JP6285866B2 - 天然複合ホルモン補充製剤および療法 - Google Patents
天然複合ホルモン補充製剤および療法 Download PDFInfo
- Publication number
- JP6285866B2 JP6285866B2 JP2014543585A JP2014543585A JP6285866B2 JP 6285866 B2 JP6285866 B2 JP 6285866B2 JP 2014543585 A JP2014543585 A JP 2014543585A JP 2014543585 A JP2014543585 A JP 2014543585A JP 6285866 B2 JP6285866 B2 JP 6285866B2
- Authority
- JP
- Japan
- Prior art keywords
- progesterone
- estradiol
- pharmaceutical composition
- solubilized
- solubilizer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940088597 hormone Drugs 0.000 title description 9
- 239000005556 hormone Substances 0.000 title description 9
- 238000002560 therapeutic procedure Methods 0.000 title description 3
- 238000002360 preparation method Methods 0.000 title description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 272
- 229960003387 progesterone Drugs 0.000 claims description 124
- 239000000186 progesterone Substances 0.000 claims description 124
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 106
- 229960005309 estradiol Drugs 0.000 claims description 104
- 229930182833 estradiol Natural products 0.000 claims description 103
- 239000000203 mixture Substances 0.000 claims description 80
- 239000002775 capsule Substances 0.000 claims description 43
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- 239000002904 solvent Substances 0.000 claims description 34
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 28
- 239000004480 active ingredient Substances 0.000 claims description 17
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 14
- 208000024891 symptom Diseases 0.000 claims description 14
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 11
- -1 diglycerides Chemical class 0.000 claims description 10
- 230000009245 menopause Effects 0.000 claims description 8
- 150000003626 triacylglycerols Chemical class 0.000 claims description 8
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 5
- 239000007903 gelatin capsule Substances 0.000 claims description 5
- 229960002446 octanoic acid Drugs 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 3
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical group CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 5
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims 3
- 238000002648 combination therapy Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 49
- 239000000499 gel Substances 0.000 description 41
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 40
- 239000000463 material Substances 0.000 description 36
- 239000002245 particle Substances 0.000 description 23
- 229960001207 micronized progesterone Drugs 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 20
- 238000002156 mixing Methods 0.000 description 19
- 238000011049 filling Methods 0.000 description 18
- 229940011871 estrogen Drugs 0.000 description 17
- 239000000262 estrogen Substances 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 239000000945 filler Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 238000002657 hormone replacement therapy Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000008186 active pharmaceutical agent Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 238000007792 addition Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000005538 encapsulation Methods 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000012298 atmosphere Substances 0.000 description 7
- 229910001873 dinitrogen Inorganic materials 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 239000011261 inert gas Substances 0.000 description 7
- 239000002736 nonionic surfactant Substances 0.000 description 7
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 229960003399 estrone Drugs 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- 239000003086 colorant Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 239000000084 colloidal system Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 229940068968 polysorbate 80 Drugs 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001457 vasomotor Effects 0.000 description 4
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 201000006828 endometrial hyperplasia Diseases 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 150000004667 medium chain fatty acids Chemical class 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000583 progesterone congener Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000000153 supplemental effect Effects 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- ZVVGLAMWAQMPDR-WVEWYJOQSA-N (8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol;hydrate Chemical compound O.OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 ZVVGLAMWAQMPDR-WVEWYJOQSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical group CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 206010027951 Mood swings Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 206010030247 Oestrogen deficiency Diseases 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 238000011953 bioanalysis Methods 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 229960003851 estradiol hemihydrate Drugs 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 210000003905 vulva Anatomy 0.000 description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 description 1
- 208000004746 Atrophic Vaginitis Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 208000008267 Peanut Hypersensitivity Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- OZPWNCNLFBVVEN-RFYLDXRNSA-N [(6s,8r,9s,10r,13s,14s,17r)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate;[(9s,13s,14s)-13-methyl-17-oxo-9,11,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate;[(8r,9 Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1.OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1.OS(=O)(=O)OC1=CC=C2C(CC[C@]3([C@H]4CCC3=O)C)=C4C=CC2=C1.C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 OZPWNCNLFBVVEN-RFYLDXRNSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000011437 continuous method Methods 0.000 description 1
- PHMQYKDOTWAOBI-UHFFFAOYSA-N decanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCC(O)=O PHMQYKDOTWAOBI-UHFFFAOYSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 229940064258 estrace Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000021153 full breakfast Nutrition 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- HBOQXIRUPVQLKX-UHFFFAOYSA-N linoleic acid triglyceride Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC HBOQXIRUPVQLKX-UHFFFAOYSA-N 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229960001652 norethindrone acetate Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 238000006385 ozonation reaction Methods 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940063238 premarin Drugs 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- RJKFOVLPORLFTN-UHFFFAOYSA-N progesterone acetate Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 RJKFOVLPORLFTN-UHFFFAOYSA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 150000004072 triols Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本出願は以下の米国仮特許出願:2011年11月23日出願の米国仮特許出願第61/563,408号「天然複合ホルモン補充療法」;2012年6月18日出願の米国仮特許出願第61/661,302号「エストラジオール製剤」;および2012年6月20日出願の米国仮特許出願第61/662,265号「プロゲステロン製剤」の優先権を主張する。前述の出願はすべてその全開示を本明細書に参照により組み入れる。
「微粒子化プロゲステロン」の語は、本明細書において用いられる場合、約15ミクロン未満のX50粒径値を有する、および/または約25ミクロン未満のX90粒径値を有する微粒子化プロゲステロンを含む。
本明細書では、以下の製剤:プロゲステロンを含まない可溶化エストラジオール;エストラジオールを含まない微粒子化プロゲステロン;部分可溶化プロゲステロンを含む微粒子化プロゲステロン;微粒子化プロゲステロンを含む可溶化エストラジオール;部分可溶化プロゲステロンと組み合わせた微粒子化プロゲステロンを含む可溶化エストラジオール;および可溶化プロゲステロンを含む可溶化エストラジオールが提供される。本明細書において提供される根本的な製剤コンセプトは、他の天然または合成形態のエストラジオールおよびプロゲステロンで用いてもよい。微粒子化の詳細、態様および実施形態を本明細書においてさらに定義する。
重要である。溶液全体の重量に対するエストラジオールの重量比も、本明細書において議論される、意図する投与量のため重要である。とくに、カプセルによって容易に投与することができるある量の溶液中のエストラジオールの標的用量を得ることが望ましい。例えば、カプセル中のエストラジオールの用量を約0.125mg〜約2mgとすることが望ましい場合、約250mg〜約400mg、好適には約300mg〜約350mg、より好適には約325mgの総溶液重量を有することも望ましい。各種実施形態では、総溶液に対するエストラジオールの重量比は、約0.125:50mg〜約0.125:1000mg、約1mg:500mg〜約1mg:50mg、約1mg:250mg〜約1mg:60mg、約1mg:100mg〜約1mg:66mg、約2mg:50mg〜約2mg:1000mgである。各種実施形態では、単回投与製品の標的は325mgであり、複合製品(例えば、2つ以上のステロールAPI)の標的充填重量は650mgである。
各種実験では、所望の目標をエストラジオールについて〜20mg/gの可溶性を達成することとし、100mgの充填物質中2mgをエストラジオールとするのに十分な可溶性を提供するために適切な溶剤を決定した。エストラジオールを各種溶剤と混合し、溶液をエストラジオールで飽和し、少なくとも3日間平衡化し、未溶解粒子を濾過し、HPLCによりエストラジオールの溶解量について透明な浮遊物を分析することにより、初期可溶性実験を行った。
200mgの総カプセル充填物質中2mgのエストラジオールを可溶化することもできる媒体中での50mgのプロゲステロンの懸濁を達成することが望ましかった。この製剤を達成するため、必要なエストラジオールの可溶性は〜10mg/gでなければらない。200mgの総充填重量はサイズ5の楕円形ソフトゼラチンカプセルに適していると考えられた。
さらなる実験を行い、表3に報告するように、溶剤混合物中のエストラジオール(4〜6mg)の安定性を評価した。4%のトランスクトールを有するミグリオール812は温/冷サイクルで96時間後に沈殿したが、30および50%のミグリオール:キャプムルのブレンド中、または単独のキャプムルMCM中に可溶化させたエストラジオールは、同じ条件下で少なくとも14日間沈殿しなかった。
時間経過に伴うエストラジオール溶液の物理的安定性の測定に加えて、カプセル化プロセス中に充填材料が安定であるかを測定することが必要である。これらの製剤を試験する1つの方法は、充填物質への水の添加である。表5でわかるように、ポリエチレングリコール400およびキャプムルMCM中6mg/gの濃度のエストラジオール溶液は少なくとも7%の水を再結晶化なしに吸収することができるが、ミグリオール812:キャプムルPG8(75:25)中の同濃度の溶液は沈殿する。
例となる実施形態では、以下の充填材料を含有するカプセルが提供される。
例となる実施形態では、以下の充填材料を含有するカプセルが提供される。
各種実施形態では、エストラジオールおよびプロゲステロンの両方を溶剤中に溶解することができる。各種実施形態では、エストラジオールおよびプロゲステロンの両方の可溶性は、適当なサイズの物質で治療効果的な用量を得ることができるように、好適にはサイズ3〜22の楕円形または長円形カプセル中への封入に適している一般的には1mg〜1200mgと考えられる。例えば、各種実施形態では、50mg〜100mgのプロゲステロンはある体積の溶剤中に溶解することができる;すなわち、可溶性はカプセル当たり50mg〜100mgである。ミグリオールを試したところ、プロゲステロンの良好な担体とみなすことができるが、単独では所望レベルのエストラジオールの可溶化は提供しなかった(例えば、各種実施形態では12mg/gの可溶性が望ましくあり得る)。よって、ミグリオールはプロゲステロンの懸濁液を含む実施形態では用いることができるが、ミグリオールは単体では完全可溶化プロゲステロンおよび/またはエストラジオールを有する実施形態において用いるには望ましくない。
例となる実施形態では、以下の完全可溶化プロゲステロンおよびエストラジオールを有する充填材料を含有するカプセルが提供される。
例となる実施形態では、以下の懸濁化プロゲステロンを有する充填材料を含有するカプセルが提供される。
例となる実施形態では、以下の懸濁化プロゲステロンを有する充填材料を含有するカプセルが提供される。
この実施例の目的のため、粒径分析はベックマン装置を用いることにより行う。各種実施形態による微粒子化プロゲステロンを含むAPI試料を分析用に提供する。
約200mgの微粒子化プロゲステロンおよび2mgのエストラジオールを有する製剤試料を油で分散させた。MLMを備えるベックマン装置で60秒間分析を行った。ベックマン装置はフラウンホーファー光学モデルを用いるように構成した。ベックマン装置は、試料が11.0μmのX50、17.3μmのX75、および5.3μmのX25を有することを示した。ベックマン装置は、平均粒径が11.8μmであり、中間粒径が11.04μmであり、モード粒径が13.6μmであり、標準偏差が7.8μmであることも示した。
最終溶液中でのプロゲステロンの可溶性を増加させるため、ゲルシール44/14を約10%w/wで添加した。
定量配合:バッチサイズ10,000カプセル
例となる実施形態では、以下の完全可溶化エストラジオールおよび部分可溶化プロゲステロンを有する充填材料を含有するカプセルが提供される。
例となる実施形態では、以下の完全可溶化エストラジオールおよび部分可溶化プロゲステロンを有する充填材料を含有するカプセルが提供される。
この以下の実験プロトコルを用い、24人の正常で健康な成人の閉経後期の女性被験者に摂食条件下で投与した、実施例14に記載されるプロセスによって調製されたプロゲステロン(200mg)およびエストラジオール(2.0mg)を含む本開示の複合製品について生物学的利用能および生物学的同等性のパラメータを構築し、200mgのプロメトリウム(PROMETRIUM;登録商標)(Catalent Pharmaceuticals、フロリダ州セントピーターズバーグ)および2.0mgのエストレース(ESTRACE;登録商標)(Bristol−Myers Squibb Co.、ニュージャージー州プリンストン)と比較した。
各種実施形態による製造方法を図1〜3に示す。図1を参照すると、充填材料の製造方法100が示される。ステップ102は油性担体を40℃±5℃まで加熱することを含む。加熱はいずれかの適切な手段によって達成することができる。加熱は、ステンレススチール容器のような、いずれかの適切な容器で行うことができる。油性担体は、本明細書に記載されるいずれかの油性担体、例えば、キャプムルMCMであってもよい。
Claims (27)
- 可溶化エストラジオール、懸濁化プロゲステロン、および可溶化剤を含む医薬組成物であって;前記エストラジオールおよび前記懸濁化プロゲステロンのそれぞれが前記可溶化剤中に存在し、前記エストラジオールおよび前記懸濁化プロゲステロンが均一に分散し;前記エストラジオールの少なくとも約90%が前記可溶化剤中で可溶化し;前記可溶化剤がグリセロールのC6〜C12脂肪酸エステルを含む油を含む、医薬組成物。
- 部分可溶化プロゲステロンをさらに含む、請求項1に記載の医薬組成物。
- 前記組成物がゼラチンカプセル内に含有される、請求項1に記載の医薬組成物。
- 前記可溶化剤がモノグリセリド、ジグリセリド、およびトリグリセリド、ならびにこれらの組み合わせから選択される、請求項1に記載の医薬組成物。
- 前記可溶化剤がモノグリセリド、ジグリセリド、およびこれらの組み合わせから選択される、請求項4に記載の医薬組成物。
- 前記モノグリセリドおよびジグリセリドがカプリル酸およびカプリン酸のエステルを含有する、請求項5に記載の医薬組成物。
- 前記エストラジオールが少なくとも約0.125mgの有効成分含量を有し、前記プロゲステロンが少なくとも約25mgの有効成分含量を有する、請求項1に記載の医薬組成物。
- プロゲステロンのエストラジオールに対する比が少なくとも約24:1、約25:1、約96:1、約100:1、約192:1、または約200:1である、請求項1に記載の医薬組成物。
- 可溶化エストラジオール、懸濁化プロゲステロン、および可溶化剤を含む、女性の閉経関連症状治療用医薬組成物であって、
前記エストラジオールおよび前記懸濁化プロゲステロンのそれぞれが前記可溶化剤中に存在し、前記エストラジオールおよび前記懸濁化プロゲステロンが均一に分散し、
前記可溶化剤がグリセロールのC6〜C12脂肪酸エステルを含む油を含み、
前記エストラジオールの少なくとも約90%が前記可溶化剤中で可溶化し、
効果的な量の前記医薬組成物が女性に投与される、
女性の閉経関連症状治療用医薬組成物。 - 部分可溶化プロゲステロンをさらに含む、請求項9に記載の医薬組成物であって、前記部分可溶化プロゲステロンが前記可溶化剤中で可溶化する、医薬組成物。
- 前記組成物がゼラチンカプセルとして製剤される、請求項9に記載の医薬組成物。
- 前記C6〜C12油がモノグリセリド、ジグリセリド、およびトリグリセリド、ならびにこれらの組み合わせから選択される、請求項9に記載の医薬組成物。
- 前記C6〜C12油がモノグリセリド、ジグリセリド、およびこれらの組み合わせから選択される、請求項12に記載の医薬組成物。
- 前記モノグリセリドおよびジグリセリドがカプリル酸およびカプリン酸のエステルを含有する、請求項13に記載の医薬組成物。
- 前記エストラジオールが少なくとも約0.125mgの有効成分含量を有し、前記プロゲステロンが少なくとも約25mgの有効成分含量を有する、請求項9に記載の医薬組成物。
- プロゲステロンのエストラジオールに対する比が約24:1、約25:1、約96:1、約100:1、約192:1、または約200:1である、請求項9に記載の医薬組成物。
- 前記組成物が200mgのプロゲステロンソフトゲルカプセルおよび2mgのエストラジオールタブレットと生物学的に同等である、請求項9に記載の医薬組成物。
- 前記組成物が連続併用療法の処方計画として投与される、請求項9に記載の医薬組成物。
- 可溶化エストラジオール、懸濁化プロゲステロンおよびグリセロールのC6〜C12脂肪酸エステルを含む油を含有する可溶化剤を含む、女性の閉経関連症状治療用医薬組成物であって、
前記エストラジオールおよび前記懸濁化プロゲステロンが、前記可溶化剤中に存在し、
前記エストラジオールが、少なくとも14日間沈殿せず、および、
前記医薬組成物が、女性に投与される、
女性の閉経関連症状治療用医薬組成物。 - 部分可溶化プロゲステロンをさらに含む、請求項19に記載の医薬組成物であって、前記部分可溶化プロゲステロンが前記可溶化剤中で可溶化する、医薬組成物。
- 前記組成物がゼラチンカプセルとして製剤される、請求項19に記載の医薬組成物。
- 前記C6〜C12油がモノ、ジ、およびトリグリセリド、ならびにこれらの組み合わせから選択される、請求項19に記載の医薬組成物。
- 前記C6〜C12油がモノグリセリド、ジグリセリド、およびこれらの組み合わせから選択される、請求項22に記載の医薬組成物。
- 前記モノグリセリドおよびジグリセリドがカプリル酸およびカプリン酸のエステルを含有する、請求項23に記載の医薬組成物。
- 前記エストラジオールが少なくとも約0.125mgの有効成分含量を有し、前記プロゲステロンが少なくとも約25mgの有効成分含量を有する、請求項19に記載の医薬組成物。
- プロゲステロンのエストラジオールに対する比が約24:1、約25:1、約96:1、約100:1、約192:1、または約200:1である、請求項19に記載の医薬組成物。
- 前記組成物が200mgのプロゲステロンソフトゲルカプセルおよび2mgのエストラジオールタブレットと生物学的に同等である、請求項19に記載の医薬組成物。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161563408P | 2011-11-23 | 2011-11-23 | |
US61/563,408 | 2011-11-23 | ||
US201261661302P | 2012-06-18 | 2012-06-18 | |
US61/661,302 | 2012-06-18 | ||
US201261662265P | 2012-06-20 | 2012-06-20 | |
US61/662,265 | 2012-06-20 | ||
PCT/US2012/066406 WO2013078422A2 (en) | 2011-11-23 | 2012-11-21 | Natural combination hormone replacement formulations and therapies |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017173842A Division JP6656215B2 (ja) | 2011-11-23 | 2017-09-11 | 天然複合ホルモン補充製剤および療法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015507607A JP2015507607A (ja) | 2015-03-12 |
JP6285866B2 true JP6285866B2 (ja) | 2018-02-28 |
Family
ID=48427194
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014543585A Active JP6285866B2 (ja) | 2011-11-23 | 2012-11-21 | 天然複合ホルモン補充製剤および療法 |
JP2017173842A Expired - Fee Related JP6656215B2 (ja) | 2011-11-23 | 2017-09-11 | 天然複合ホルモン補充製剤および療法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017173842A Expired - Fee Related JP6656215B2 (ja) | 2011-11-23 | 2017-09-11 | 天然複合ホルモン補充製剤および療法 |
Country Status (15)
Country | Link |
---|---|
US (13) | US8633178B2 (ja) |
EP (2) | EP2782584B1 (ja) |
JP (2) | JP6285866B2 (ja) |
BR (1) | BR112014012444B1 (ja) |
CA (1) | CA2856520C (ja) |
ES (1) | ES2885523T3 (ja) |
FR (1) | FR21C1058I2 (ja) |
HR (1) | HRP20211377T1 (ja) |
HU (1) | HUE055562T2 (ja) |
LT (1) | LT2782584T (ja) |
MX (1) | MX365818B (ja) |
PL (1) | PL2782584T3 (ja) |
PT (1) | PT2782584T (ja) |
RS (1) | RS62297B1 (ja) |
WO (1) | WO2013078422A2 (ja) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9795617B2 (en) | 2009-06-18 | 2017-10-24 | Baucom Institute for Longevity and Life Enhancement, Inc. | Hormone delivery system and method |
JP6285866B2 (ja) | 2011-11-23 | 2018-02-28 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然複合ホルモン補充製剤および療法 |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
WO2013192249A1 (en) * | 2012-06-18 | 2013-12-27 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20140370084A1 (en) * | 2013-06-18 | 2014-12-18 | Therapeuticsmd, Inc. | Estradiol formulations and therapies |
JP6680672B2 (ja) * | 2013-10-10 | 2020-04-15 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 膣挿入されるエストラジオール薬学的組成物及び方法 |
WO2015130807A1 (en) * | 2014-02-25 | 2015-09-03 | Baucom Institute for Longevity and Life Enhancement, Inc. | Hormone delivery system and method |
CN106232107B (zh) * | 2014-05-05 | 2020-06-05 | 艾尔建制药国际有限公司 | 用于抗孕激素的阴道递送的制剂和方法 |
CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
AU2015296609A1 (en) * | 2014-07-29 | 2016-12-22 | Therapeuticsmd, Inc. | Transdermal cream |
US10328087B2 (en) * | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
MX2018011706A (es) * | 2016-04-01 | 2019-06-10 | Therapeuticsmd Inc | Composicion farmaceutica de hormona esteroide. |
JP2019513709A (ja) * | 2016-04-01 | 2019-05-30 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | ステロイドホルモン薬学的組成物 |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US10285998B1 (en) | 2018-04-04 | 2019-05-14 | The Menopause Method, Inc. | Composition and method to aid in hormone replacement therapy |
WO2020081726A1 (en) * | 2018-10-17 | 2020-04-23 | Stadler Sarah Sheehan | Methods of treating menopausal symptoms using low dose progesterone |
CA3117842A1 (en) | 2018-10-26 | 2020-04-30 | Viramal Limited | Mucoadhesive gel composition |
ES2948955T3 (es) | 2018-11-30 | 2023-09-22 | Viramal Ltd | Un método de preparación de un agente gelificante, el agente gelificante obtenido de este modo y el uso de dicho agente gelificante |
EP3947338A4 (en) * | 2019-03-27 | 2023-01-04 | Kemin Industries, Inc. | PROCESS FOR THE PREPARATION OF METAL CARBOXYLATES IN A ONE-POT REACTION |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
US11337987B1 (en) | 2021-05-07 | 2022-05-24 | Lipocine Inc. | Compositions and methods for treating central nervous system disorders |
GB2626266A (en) | 2021-10-08 | 2024-07-17 | Chemo Res S L | Oral pharmaceutical compositions of progesterone and estradiol |
Family Cites Families (1185)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1967351A (en) | 1930-10-06 | 1934-07-24 | President And Board | Hormone and process of obtaining the same |
US2232438A (en) | 1934-08-04 | 1941-02-18 | Schering Corp | Unsaturated pregnanolones and pregnandiones and a method of producing the same |
GB452238A (en) | 1934-08-24 | 1936-08-19 | Chem Ind Basel | Process for purifying progesterone preparations |
US2379832A (en) | 1936-06-02 | 1945-07-03 | Schering Corp | Process for the manufacture of unsaturated ketones of the cyclopentano polyhydro phenanthrene series |
US2649399A (en) | 1951-02-01 | 1953-08-18 | Ayerst Mckenna & Harrison | Conjugated oestrogenic quaternary ammonium salts and their preparation |
GB720561A (en) | 1952-04-17 | 1954-12-22 | Frederick Victor Wells | Improvements in preparations for application to the hair and scalp |
GB848881A (en) | 1955-12-27 | 1960-09-21 | Upjohn Co | Improvements in or relating to hormone compositions and the preparation thereof |
GB874368A (en) | 1957-12-09 | 1961-08-02 | Irwin Irville Lubowe | Improvements in anti-seborrheic and scalp preparations |
FR1368727A (fr) | 1961-05-04 | 1964-08-07 | Roussel Uclaf | Dérivés de l'estradiol et procédé de préparation |
US3916898A (en) | 1964-05-20 | 1975-11-04 | Searle & Co | Administration of medicaments and the like |
US3755575A (en) | 1965-01-26 | 1973-08-28 | Squibb & Sons Inc | Pharmaceutical compositions |
FR5519M (ja) | 1966-06-07 | 1967-11-06 | ||
US3478070A (en) | 1967-12-26 | 1969-11-11 | American Home Prod | Process for selectively acylating the 3-ol group in polyhydroxy 13-alkyl gona-(and 8 - isogona) - 1,3,5 - (10) - trienes and delta - 7 -,delta - 8(9),delta - 9(11) -,and delta - 8(9),14(15) - dehydro derivatives thereof |
GB1261348A (en) | 1968-04-02 | 1972-01-26 | Leo Ab | Treatment of hair and scalp and compositions therefor |
US3755573A (en) | 1970-07-10 | 1973-08-28 | Warner Lambert Co | Fertility control empoying quinestrol and quingestanol acetate |
US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
US3903880A (en) | 1972-08-17 | 1975-09-09 | Alza Corp | Intrauterine device for managing the reproductive process |
US3923997A (en) | 1971-05-11 | 1975-12-02 | Rhodia | Process for repelling dogs and cats from a selected area or from each other using {65 -n-alkyl-{65 -butyrolactones and {67 -n-alkyl-{67 -valerolactones |
US3729566A (en) | 1971-05-25 | 1973-04-24 | Upjohn Co | Rodent sterilant process |
US3948254A (en) | 1971-11-08 | 1976-04-06 | Alza Corporation | Novel drug delivery device |
US4016251A (en) | 1972-08-17 | 1977-04-05 | Alza Corporation | Vaginal drug dispensing device |
US3971367A (en) | 1972-12-27 | 1976-07-27 | Alza Corporation | Intrauterine device having means for changing from uterine-retentive shape to nonuterine-retentive shape |
US3921636A (en) | 1973-01-15 | 1975-11-25 | Alza Corp | Novel drug delivery device |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4014987A (en) | 1974-06-04 | 1977-03-29 | Alza Corporation | Device for delivery of useful agent |
US3993072A (en) | 1974-08-28 | 1976-11-23 | Alza Corporation | Microporous drug delivery device |
US4155991A (en) | 1974-10-18 | 1979-05-22 | Schering Aktiengesellschaft | Vaginal ring |
IL48277A (en) | 1974-10-18 | 1978-03-10 | Schering Ag | Vaginal ring |
US4093709A (en) | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
NL7506407A (nl) | 1975-05-30 | 1976-12-02 | Akzo Nv | Werkwijze ter bereiding van een oraal werkzaam far- maceutisch preparaat. |
US3977404A (en) | 1975-09-08 | 1976-08-31 | Alza Corporation | Osmotic device having microporous reservoir |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4014334A (en) | 1976-02-02 | 1977-03-29 | Alza Corporation | Laminated osmotic system for dispensing beneficial agent |
US4154820A (en) | 1976-02-23 | 1979-05-15 | Akzona Incorporated | Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers |
US4217885A (en) | 1976-04-12 | 1980-08-19 | Solartrap, Inc. | Solar heat collection |
FR2408345A1 (fr) | 1976-11-30 | 1979-06-08 | Besins Jean Louis | Nouvelle composition a action anti-conceptionnelle |
US4310510A (en) | 1976-12-27 | 1982-01-12 | Sherman Kenneth N | Self administrable anti-fertility composition |
US4393871A (en) | 1977-06-27 | 1983-07-19 | Vli Corporation | Vaginal device |
GB1589946A (en) | 1977-12-14 | 1981-05-20 | Kali Chemie Pharma Gmbh | Enterally absorbable preparations and process for the production thereof |
US4215691A (en) | 1978-10-11 | 1980-08-05 | Alza Corporation | Vaginal contraceptive system made from block copolymer |
US4732763A (en) | 1978-10-17 | 1988-03-22 | Stolle Research And Development Corporation | Active/passive immunization of the internal female reproductive organs |
US4756907A (en) | 1978-10-17 | 1988-07-12 | Stolle Research & Development Corp. | Active/passive immunization of the internal female reproductive organs |
US4237885A (en) | 1978-10-23 | 1980-12-09 | Alza Corporation | Delivery system with mated members for storing and releasing a plurality of beneficial agents |
US4384096A (en) | 1979-08-27 | 1983-05-17 | The Dow Chemical Company | Liquid emulsion polymers useful as pH responsive thickeners for aqueous systems |
US4372951A (en) | 1979-10-11 | 1983-02-08 | Nichols Vorys | Vaginal delivery for physiologic follicular-luteal steroid treatment |
US4402695A (en) | 1980-01-21 | 1983-09-06 | Alza Corporation | Device for delivering agent in vagina |
GB2079158B (en) | 1980-06-09 | 1985-01-09 | Ahi Operations Ltd | Intra-vaginal devices |
DE3040978A1 (de) | 1980-10-28 | 1982-05-27 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Vaginalring |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4423151A (en) | 1981-09-24 | 1983-12-27 | Peter S. Brune | Process for preparation of control for use in estrogen receptor tests |
US4629449A (en) | 1982-07-29 | 1986-12-16 | Alza Corporation | Vaginal dispenser for dispensing beneficial hormone |
US4961931A (en) | 1982-07-29 | 1990-10-09 | Alza Corporation | Method for the management of hyperplasia |
US4826831A (en) | 1983-08-05 | 1989-05-02 | Pre Jay Holdings Limited | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens |
US6309669B1 (en) | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
US4610687A (en) | 1984-08-06 | 1986-09-09 | Board Of Trustees Operating Michigan State University | Method for breeding control in female bovines |
DE3510555A1 (de) | 1985-03-21 | 1986-09-25 | Schering AG, 1000 Berlin und 4709 Bergkamen | Estriolester |
US4816257A (en) | 1985-09-20 | 1989-03-28 | Research & Education Institute, Harbor-Ucla Medical Center Inc. | Method for producing an in vivo environment suitable for human embryo transfer |
US5208225A (en) | 1986-02-27 | 1993-05-04 | Warner-Lambert Company | Compositions containing fixed combinations |
US4762717A (en) | 1986-03-21 | 1988-08-09 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive |
US5140021A (en) | 1986-04-16 | 1992-08-18 | Genesis Systems Corporation | Method and dosage form for treatment of premenstrual syndrome |
US4963540A (en) | 1986-04-16 | 1990-10-16 | Maxson Wayne S | Method for treatment of premenstrual syndrome |
US5145682A (en) | 1986-05-30 | 1992-09-08 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration |
US4908389A (en) | 1986-08-27 | 1990-03-13 | Warner-Lambert Company | Penetration enhancement system |
US6139868A (en) | 1986-08-28 | 2000-10-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system, its use and production process |
CN1021196C (zh) | 1986-12-29 | 1993-06-16 | 新泽西州州立大学(鲁杰斯) | 透皮雌激素/孕激素药剂单元、系统及方法 |
US4876249A (en) | 1987-01-12 | 1989-10-24 | Rajadhyaksha Vithal J | Compositions and method comprising heterocyclic compounds containing two heteroatoms |
US4788062A (en) | 1987-02-26 | 1988-11-29 | Alza Corporation | Transdermal administration of progesterone, estradiol esters, and mixtures thereof |
US4865848A (en) | 1987-02-26 | 1989-09-12 | Alza Corporation | Skin permeation enhancer compositions using sucrose esters |
US5538736A (en) | 1987-04-28 | 1996-07-23 | Lts Lohmann Therapie-Systeme Gmbh | Active substance-containing plaster for the controlled administration of active substances to the skin |
US4900734A (en) * | 1987-08-27 | 1990-02-13 | Maxson Wayne S | Novel pharmaceutical composition containing estradiol and progesterone for oral administration |
US5276022A (en) | 1987-09-24 | 1994-01-04 | Jencap Research Ltd. | Hormone preparation and method |
US5108995A (en) | 1987-09-24 | 1992-04-28 | Jencap Research Ltd. | Hormone preparation and method |
US5064654A (en) | 1989-01-11 | 1991-11-12 | Ciba-Geigy Corporation | Mixed solvent mutually enhanced transdermal therapeutic system |
US4906475A (en) | 1988-02-16 | 1990-03-06 | Paco Pharmaceutical Services | Estradiol transdermal delivery system |
US5656286A (en) | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5474783A (en) | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US4942158A (en) | 1988-10-13 | 1990-07-17 | Eastman Kodak | Transdermal steroid penetrant compositions and methods utilizing isopropanol and isobutanol |
DE58909570D1 (de) | 1988-10-27 | 1996-02-22 | Schering Ag | Mittel zur transdermalen applikation enthaltend gestoden |
US5164416A (en) | 1989-02-03 | 1992-11-17 | Lintec Corporation | Transdermal therapeutic formulation containing a limonene |
JP2651616B2 (ja) | 1989-02-03 | 1997-09-10 | リンテック株式会社 | 経皮吸収製剤 |
US5059426A (en) | 1989-03-22 | 1991-10-22 | Cygnus Therapeutic Systems | Skin permeation enhancer compositions, and methods and transdermal systems associated therewith |
US4973468A (en) | 1989-03-22 | 1990-11-27 | Cygnus Research Corporation | Skin permeation enhancer compositions |
JP2910857B2 (ja) | 1989-04-04 | 1999-06-23 | ニチバン株式会社 | プロスタグランジンe1経皮吸収製剤 |
DE3916112A1 (de) | 1989-05-16 | 1990-11-22 | Schering Ag | Dihydrospirorenon als antiandrogen |
DE69010076T2 (de) | 1989-05-25 | 1994-12-08 | Takeda Chemical Industries Ltd | Transdermales therapeutisches Mittel. |
US5043331A (en) | 1989-06-15 | 1991-08-27 | Orion-Yhtyma Oy | Treatment of postmenopausal disorders |
DE69007886T2 (de) | 1989-07-21 | 1994-11-17 | Izhak Blank | Östradiol enthaltende Mittel und Verfahren zur topischen Anwendung. |
US5130137A (en) | 1989-08-09 | 1992-07-14 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders |
US6004330A (en) | 1989-08-16 | 1999-12-21 | Medtronic, Inc. | Device or apparatus for manipulating matter |
US5252334A (en) | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
CA1340994C (en) | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Treatment of conditions and disease |
DE3933460A1 (de) | 1989-10-06 | 1991-04-18 | Lohmann Therapie Syst Lts | Oestrogenhaltiges wirkstoffpflaster |
US5288496A (en) | 1990-05-15 | 1994-02-22 | Stolle Research & Development Corporation | Growth promoters for animals |
AU653156B2 (en) | 1990-06-14 | 1994-09-22 | Dermamed | Transdermal administration to humans and animals |
DE4104385C1 (ja) | 1991-02-09 | 1992-08-13 | Marika Dr.Med. 6509 Framersheim De Ehrlich | |
FR2673840A1 (fr) | 1991-03-14 | 1992-09-18 | Lvmh Rech | Composition cosmetique ou pharmaceutique, notamment dermatologique, contenant de l'oxyacanthine, en particulier destinee a stimuler la pousse des cheveux ou a retarder leur chute. |
US5340586A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Methods and formulations for use in treating oophorectomized women |
US5340585A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
US5211952A (en) | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
US6342491B1 (en) | 1991-05-21 | 2002-01-29 | American Home Products Corporation | Method of treating estrogen receptor positive carcinoma with 17 α-dihydroequilin |
GB9113726D0 (en) | 1991-06-25 | 1991-08-14 | Inst Of Animal Physiology And | Artificial animal foster mothers |
US5653983A (en) | 1991-07-19 | 1997-08-05 | Lvmh Recherche | Compositions for the pigmentation of the skin or of the hair containing an extract of Marrubium vulgare, the process for it's manufacture and it's |
US5676968A (en) | 1991-10-31 | 1997-10-14 | Schering Aktiengesellschaft | Transdermal therapeutic systems with crystallization inhibitors |
WO1993010768A1 (de) | 1991-12-05 | 1993-06-10 | Alfatec-Pharma Gmbh | Pharmazeutisch applizierbares nanosol und verfahren zu seiner herstellung |
US7704983B1 (en) | 1992-03-02 | 2010-04-27 | Eastern Virginia Medical School | Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception |
MX9301121A (es) | 1992-03-02 | 1993-09-01 | Schering Ag | Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina. |
US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
US5453279A (en) | 1992-04-21 | 1995-09-26 | Tbs Laboratories, Inc. | Enhancing transdermal absorption compositions; transdermal dosage form; and process |
US5393528A (en) | 1992-05-07 | 1995-02-28 | Staab; Robert J. | Dissolvable device for contraception or delivery of medication |
US5607691A (en) | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
US5295945A (en) | 1992-08-03 | 1994-03-22 | Beth Israel Hospital Assoc. Inc. | Garment and method for positioning and securing a radioactive implant internally within the female genital organs |
FR2695561B1 (fr) | 1992-09-17 | 1994-12-02 | Lvmh Rech Gie | Composition cosmétique ou dermatologique contenant au moins une saponine de type ginsenoside, et ses applications, notamment pour le soin des cheveux. |
ATE255726T1 (de) | 1992-09-28 | 2003-12-15 | Biex Inc | Verfahren zur vorhersage von frühgeburten |
US5811547A (en) | 1992-10-14 | 1998-09-22 | Nippon Shinyaju Co., Ltd. | Method for inducing crystalline state transition in medicinal substance |
AU5541594A (en) | 1992-10-21 | 1994-05-09 | Gynetech Laboratories, Inc. | Vaginal sponge delivery system |
US5639743A (en) | 1992-11-13 | 1997-06-17 | University Of Georgia Research Foundation | Compositions and methods for treating exocrine gland atrophy |
FR2699406B1 (fr) | 1992-12-21 | 1995-03-10 | Commissariat Energie Atomique | Films à base de copolymères, leurs applications dans des systèmes transdermiques et leurs procédés de préparation. |
MY113268A (en) | 1992-12-29 | 2002-01-31 | Insite Vision Incorporated | Plasticized bioerodible controlled delivery system |
DE4301783C1 (de) | 1993-01-23 | 1994-02-03 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil |
US5843979A (en) | 1993-02-25 | 1998-12-01 | Bristol-Myers Squibb Company | Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity |
US5468736A (en) | 1993-02-25 | 1995-11-21 | The Medical College Of Hampton Road | Hormone replacement therapy |
SE9301171D0 (sv) | 1993-04-07 | 1993-04-07 | Ab Astra | Pharmaceutical composition containing lipophilic drugs |
US5762952A (en) | 1993-04-27 | 1998-06-09 | Hercon Laboratories Corporation | Transdermal delivery of active drugs |
DE4336557C2 (de) | 1993-05-06 | 1997-07-17 | Lohmann Therapie Syst Lts | Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung |
FI95768C (fi) | 1993-06-17 | 1996-03-25 | Leiras Oy | Emättimensisäinen antosysteemi |
US5595970A (en) | 1993-07-16 | 1997-01-21 | Schering Aktiengesellschaft | Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors |
DK95093D0 (da) | 1993-08-20 | 1993-08-20 | Novo Nordisk As | Farmaceutisk formulering indeholdende et hormon |
DE4329242A1 (de) | 1993-08-26 | 1995-03-02 | Schering Ag | Mittel zur transdermalen Applikation enthaltend Gestodenester |
US5543150A (en) | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
AU679793B2 (en) | 1993-09-29 | 1997-07-10 | Alza Corporation | Monoglyceride/lactate ester permeation enhancer |
DE4341444C2 (de) | 1993-12-04 | 1996-03-14 | Lohmann Therapie Syst Lts | Wirkstoffhaltiges Pflaster und Verfahren zu seiner Herstellung |
DE4344463A1 (de) | 1993-12-22 | 1995-06-29 | Schering Ag | Kombinationsprodukt zur Kontrazeption |
DE4344405C2 (de) | 1993-12-24 | 1995-12-07 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption |
DE4400770C1 (de) | 1994-01-13 | 1995-02-02 | Lohmann Therapie Syst Lts | Wirkstoffhaltiges Pflaster zur Abgabe von Estradiol mit mindestens einem Penetrationsverstärker, Verfahren zu seiner Herstellung und seine Verwendung |
DE4405898A1 (de) | 1994-02-18 | 1995-08-24 | Schering Ag | Transdermale therapeutische Systeme enthaltend Sexualsteroide |
US6228383B1 (en) | 1994-03-03 | 2001-05-08 | Gs Development Ab | Use of fatty acid esters as bioadhesive substances |
WO1995024172A1 (en) | 1994-03-07 | 1995-09-14 | Theratech, Inc. | Drug-containing adhesive composite transdermal delivery device |
GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
FR2717689B1 (fr) | 1994-03-28 | 1996-07-05 | Lhd Lab Hygiene Dietetique | Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base de copolymère styrène-isoprène-styrène. |
FR2717688B1 (fr) | 1994-03-28 | 1996-07-05 | Lhd Lab Hygiene Dietetique | Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA. |
CA2582666C (en) | 1994-04-08 | 2010-05-25 | Qlt Usa, Inc. | Controlled release implant |
WO1995028144A1 (en) | 1994-04-13 | 1995-10-26 | Ciba-Geigy Ag | Temporally controlled drug delivery systems |
US6538039B2 (en) | 1994-04-29 | 2003-03-25 | Laboratoire L. Lafon | Pharmaceutical dosage form for transdermal administration |
WO1995030409A1 (en) | 1994-05-05 | 1995-11-16 | Merck Frosst Canada Inc. | Topical polymeric drug delivery system |
US5811416A (en) | 1994-06-06 | 1998-09-22 | Board Of Regents The University Of Texas System | Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate |
US5709844A (en) | 1994-06-09 | 1998-01-20 | The Regents Of The University Of California | Transgenic mice expressing HPV early region oncogene develop progressive cervico-vaginal neoplasia |
US5869084A (en) | 1994-06-20 | 1999-02-09 | K-V Pharmaceuticals Co. | Multi-vitamin and mineral supplements for women |
JPH11505504A (ja) | 1994-06-27 | 1999-05-21 | イオニックス・コーポレーション | ホウ素を含有するホルモン類似体及びホルモン受容体を有する細胞をイメージング若しくは殺すためにこれらを使用する方法 |
FR2722102B1 (fr) | 1994-07-11 | 1996-08-23 | Cird Galderma | Utilisation de particules creuses deformables dans une composition cosmetique et/ou dermatologique, contenant des matieres grasses |
FR2722984B1 (fr) | 1994-07-26 | 1996-10-18 | Effik Lab | Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees |
US5633011A (en) | 1994-08-04 | 1997-05-27 | Alza Corporation | Progesterone replacement therapy |
US6586006B2 (en) | 1994-08-04 | 2003-07-01 | Elan Drug Delivery Limited | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
DE4429374C1 (de) | 1994-08-12 | 1996-02-01 | Jenapharm Gmbh | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
US5762614A (en) | 1994-08-25 | 1998-06-09 | Caillouette; James C. | Estrogen or estradiol need determination by vaginal acidity determination |
US5916176A (en) | 1994-08-25 | 1999-06-29 | Caillouette; James C. | Estrogen or estradiol need determination by vaginal or urethral acidity determination |
US5827200A (en) | 1997-01-27 | 1998-10-27 | Caillouette; James C. | Method and apparatus for detecting amine producing organisms in the vagina |
US6402705B1 (en) | 1994-08-25 | 2002-06-11 | James C. Caillouette | Body moisture test apparatus and method |
US5735801A (en) | 1994-08-25 | 1998-04-07 | Caillouette; James C. | Estrogen or estradiol need determination by vaginal acidity determination |
US5856603A (en) | 1994-08-26 | 1999-01-05 | Engelhard Corporation | Process for the production of cyclohexane |
AU702593B2 (en) | 1994-09-14 | 1999-02-25 | Minnesota Mining And Manufacturing Company | Matrix for transdermal drug delivery |
US6613757B1 (en) | 1994-09-22 | 2003-09-02 | Board Of Regents, The University Of Texas System | Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy |
US6716454B2 (en) | 1994-09-23 | 2004-04-06 | Laboratorie Innothera, Société Anonyme | Therapeutic combination of vitamin and calcium in unitary galenic tablet form, a method of obtaining it, and the use thereof |
IL115445A (en) | 1994-10-17 | 1999-08-17 | Akzo Nobel Nv | Solid pharmaceutical compositions comprising low dosage active ingredient oil and excipient capable of binding water and their preparation |
FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
US5595759A (en) | 1994-11-10 | 1997-01-21 | Alza Corporation | Process for providing therapeutic composition |
US5571933A (en) | 1994-11-17 | 1996-11-05 | Duquesne University Of The Holy Ghost | Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use |
WO1996015776A1 (fr) | 1994-11-18 | 1996-05-30 | Hisamitsu Pharmaceutical Co., Inc. | Timbre absorbable par voie percutanee |
US5686100A (en) | 1994-11-22 | 1997-11-11 | E.R. Squibb & Sons, Inc. | Prophylactic and therapeutic treatment of skin sensitization and irritation |
US5885974A (en) | 1994-12-06 | 1999-03-23 | Michael M. Danielov | Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor |
FR2728463A1 (fr) | 1994-12-21 | 1996-06-28 | Lhd Lab Hygiene Dietetique | Systeme transdermique d'administration simultanee de plusieurs principes actifs |
FR2728464B1 (fr) | 1994-12-22 | 1997-04-30 | Innothera Lab Sa | Forme galenique unitaire, son procede d'obtention et ses utilisations |
US6344211B1 (en) | 1994-12-24 | 2002-02-05 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal absorption of active substances from subcooled melts |
DE4446600A1 (de) | 1994-12-24 | 1996-06-27 | Lohmann Therapie Syst Lts | Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen |
US6024974A (en) | 1995-01-06 | 2000-02-15 | Noven Pharmaceuticals, Inc. | Composition and methods for transdermal delivery of acid labile drugs |
DE19500662C2 (de) | 1995-01-12 | 2001-04-26 | Lohmann Therapie Syst Lts | Estradiolhaltiges Pflaster und seine Verwendung |
US5516528A (en) | 1995-01-13 | 1996-05-14 | Wake Forest University | Dietary phytoestrogen in estrogen replacement therapy |
US5547948A (en) | 1995-01-17 | 1996-08-20 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
FR2729854A1 (fr) | 1995-01-26 | 1996-08-02 | Oreal | Utilisation du sulfate de dehydroepi-androsterone dans une composition cosmetique ou dermatologique |
US5629021A (en) | 1995-01-31 | 1997-05-13 | Novavax, Inc. | Micellar nanoparticles |
US5565199A (en) | 1995-02-07 | 1996-10-15 | Page; Elliot W. | Systems and methods for the synthesis of natural base steroidal hormones and more especially estrogens and progesterone and estrogen-like and progesterone-like compounds and their derivatives derived as phytohormones from herbaceous plants |
US5609617A (en) | 1995-02-21 | 1997-03-11 | C. Norman Shealy | Method for enhancement of dehydroepiandrosterone |
FR2732223B1 (fr) | 1995-03-30 | 1997-06-13 | Sanofi Sa | Composition pharmaceutique pour administration transdermique |
MY118354A (en) | 1995-05-01 | 2004-10-30 | Scarista Ltd | 1,3-propane diol derivatives as bioactive compounds |
US5912268A (en) | 1995-05-22 | 1999-06-15 | Alza Corporation | Dosage form and method for treating incontinence |
US6262115B1 (en) | 1995-05-22 | 2001-07-17 | Alza Coporation | Method for the management of incontinence |
US5882676A (en) | 1995-05-26 | 1999-03-16 | Alza Corporation | Skin permeation enhancer compositions using acyl lactylates |
US5693335A (en) | 1995-06-07 | 1997-12-02 | Cygnus, Inc. | Skin permeation enhancer composition for use with sex steroids |
US5785991A (en) | 1995-06-07 | 1998-07-28 | Alza Corporation | Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate |
US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
US7833543B2 (en) | 1995-06-07 | 2010-11-16 | Durect Corporation | High viscosity liquid controlled delivery system and medical or surgical device |
US5780050A (en) | 1995-07-20 | 1998-07-14 | Theratech, Inc. | Drug delivery compositions for improved stability of steroids |
DE19526864A1 (de) | 1995-07-22 | 1997-01-23 | Labtec Gmbh | Hormonpflaster |
US5679573A (en) | 1995-07-27 | 1997-10-21 | Abbott Laboratories | Stabilized aqueous steroid immunoassay standards with cyclodextrins |
US6245347B1 (en) | 1995-07-28 | 2001-06-12 | Zars, Inc. | Methods and apparatus for improved administration of pharmaceutically active compounds |
US5567831A (en) | 1995-08-16 | 1996-10-22 | Duguesne University Of The Holy Ghost | Non-steroidal sulfatase inhibitor compounds and their method of use |
US5840327A (en) | 1995-08-21 | 1998-11-24 | Alza Corporation | Transdermal drug delivery device having enhanced adhesion |
US5906830A (en) | 1995-09-08 | 1999-05-25 | Cygnus, Inc. | Supersaturated transdermal drug delivery systems, and methods for manufacturing the same |
US5902603A (en) | 1995-09-14 | 1999-05-11 | Cygnus, Inc. | Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use |
FR2739032B1 (fr) | 1995-09-27 | 1997-11-21 | Lhd Lab Hygiene Dietetique | Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base d'eva, procede de preparation et utilisation en therapeutique |
FR2739031B1 (fr) | 1995-09-27 | 1997-11-21 | Lhd Lab Hygiene Dietetique | Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique |
US6551611B2 (en) | 1995-09-28 | 2003-04-22 | Schering Aktiengesellschaft | Hormone replacement therapy method |
US5922349A (en) | 1995-09-28 | 1999-07-13 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
FR2739559B1 (fr) | 1995-10-05 | 1997-11-28 | Innothera Lab Sa | Gel pour hormonotherapie locale de la secheresse vaginale |
FR2739558B1 (fr) | 1995-10-05 | 1997-11-28 | Innothera Lab Sa | Forme galenique unitaire pour hormonotherapie locale de la secheresse vaginale |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
DE19540253C2 (de) | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene |
GB9522403D0 (en) | 1995-11-01 | 1996-01-03 | Hoechst Roussel Ltd | Intravaginal drug delivery device |
US5612051A (en) | 1995-11-17 | 1997-03-18 | Yue; Samuel K. | Method of treating involuntary muscle dysfunction with relaxin hormone |
US5770176A (en) | 1995-12-08 | 1998-06-23 | Chiron Diagnostics Corporation | Assays for functional nuclear receptors |
DE19549264A1 (de) | 1995-12-23 | 1997-06-26 | Schering Ag | Verfahren und Kit zur Kontrazeption |
DE19548332A1 (de) | 1995-12-22 | 1997-07-10 | Rotta Res Bv | Hormonpflaster |
US5789442A (en) | 1996-01-18 | 1998-08-04 | Schering Aktiengesellschaft | Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents |
EP0785211A1 (en) | 1996-01-22 | 1997-07-23 | Laboratoire Theramex | New substituted 19-nor-pregnane derivatives |
EP0785212A1 (en) | 1996-01-22 | 1997-07-23 | Laboratoire Theramex | New 19-nor-pregnene derivatives |
AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US5898038A (en) | 1996-03-19 | 1999-04-27 | Board Of Regents, The University Of Texas System | Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors |
FR2747042B1 (fr) * | 1996-04-05 | 1998-06-05 | Besins Iscovesco Lab | Medicament a base de progesterone et d'oestradiol |
GB9608719D0 (en) | 1996-04-26 | 1996-07-03 | Scherer Ltd R P | Pharmaceutical compositions |
NZ286492A (en) | 1996-05-01 | 1998-02-26 | Dec International Nz Ltd Subst | Intra vaginal devices for synchronising oestrus of animals is made up of cured silicone rubber material with 5% by weight of progesterone |
US6040340A (en) | 1996-05-07 | 2000-03-21 | Schering Aktiengesellschaft | Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors |
US5962445A (en) | 1996-05-09 | 1999-10-05 | Amrad Operations Pty Ltd. | Treatment of asthma and airway diseases |
CA2256365A1 (en) | 1996-05-22 | 1997-11-27 | Diversified Pharmaceuticals, Inc. | Compositions, methods and devices for the transdermal delivery of drugs |
US5744463A (en) | 1996-06-03 | 1998-04-28 | Bair; Glenn O. | Treatment of side effects of progestins and progesterone analogues used for birth control |
IT1283102B1 (it) | 1996-06-06 | 1998-04-07 | Permatec Nv | Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele |
US6506390B2 (en) | 1996-06-25 | 2003-01-14 | Akzo Nobel | Progestogen-anti-progestogen regimens |
US6139873A (en) | 1996-07-10 | 2000-10-31 | Cedars-Sinai Medical Center | Combined pharmaceutical estrogen-androgen-progestin |
DE19629468A1 (de) | 1996-07-11 | 1998-01-15 | Schering Ag | Transdermale therapeutische Systeme |
US6228852B1 (en) | 1996-07-12 | 2001-05-08 | Carolyn V. Shaak | Transdermal application of naturally occurring steroid hormones |
EP1506775A1 (en) | 1996-07-22 | 2005-02-16 | Renovo Limited | Use of sex steroid function modulators to treat wounds and fibrotic disorders |
US5972372A (en) | 1996-07-31 | 1999-10-26 | The Population Council, Inc. | Intravaginal rings with insertable drug-containing core |
US6227202B1 (en) | 1996-09-03 | 2001-05-08 | Maulana Azad Medical College | Method of organogenesis and tissue regeneration/repair using surgical techniques |
EP0931263A1 (en) | 1996-09-06 | 1999-07-28 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Method of screening for side effects of anticonceptives or estrogen and/or progesterone replacements or supplements |
US6028064A (en) | 1996-09-13 | 2000-02-22 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of progestin products |
FR2753626B1 (fr) | 1996-09-20 | 1998-11-06 | Centre International De Rech Dermatologiques Galderma Cird Galderma | Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant |
SE9603669D0 (sv) | 1996-10-08 | 1996-10-08 | Astra Ab | New combination |
ATE319419T1 (de) | 1996-10-18 | 2006-03-15 | Union Camp Corp | Ester-terminierte polyamidgele |
US5912009A (en) | 1996-10-30 | 1999-06-15 | Theratech, Inc. | Fatty acid esters of glycolic acid and its salts |
US5985861A (en) | 1996-11-04 | 1999-11-16 | Columbia Laboratories, Inc. | Progesterone for treating or reducing ischemia |
US5928666A (en) | 1996-11-12 | 1999-07-27 | Cygnus Inc. | Crystalline form of estradiol and pharmaceutical formulations comprising same |
US5942243A (en) | 1996-11-12 | 1999-08-24 | Polytherapeutics, Inc. | Mucoadhesive compositions for administration of biologically active agents to animal tissue |
US5814329A (en) | 1996-11-12 | 1998-09-29 | Polytherapeutics, Inc. | Hydrophilic polystyrene graft copolymer vehicle for intravaginal administration of pharmacologically active agents |
US20060014728A1 (en) | 1996-11-21 | 2006-01-19 | Kristof Chwalisz | Hormone replacement therapy |
DE19654609A1 (de) | 1996-12-20 | 1998-06-25 | Schering Ag | Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder |
DE19701949A1 (de) | 1997-01-13 | 1998-07-16 | Jenapharm Gmbh | Transdermales therapeutisches System |
DE19700913C2 (de) | 1997-01-14 | 2001-01-04 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System zur Abgabe von Hormonen |
US6416778B1 (en) | 1997-01-24 | 2002-07-09 | Femmepharma | Pharmaceutical preparations and methods for their regional administration |
US5993856A (en) | 1997-01-24 | 1999-11-30 | Femmepharma | Pharmaceutical preparations and methods for their administration |
KR100215027B1 (ko) | 1997-01-27 | 1999-08-16 | 성재갑 | 스테로이드계 약물의 경피흡수투여용 조성물 및 이를 포함하는 경피흡수투여용 제형 |
US20010023261A1 (en) | 1997-01-27 | 2001-09-20 | Lg Chemical Limited. | Novel composition for the transdermal administration of drugs |
FR2759292B1 (fr) | 1997-02-10 | 2000-08-11 | Cird Galderma | Utilisation de retinoides en tant qu'agents induisant la pigmentation |
DE19705229C2 (de) | 1997-02-12 | 1999-04-15 | Hesch Rolf Dieter Prof Dr Med | Verwendung von drei Hormonkomponenten zur hormonalen Kontrazeption zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
US6056972A (en) | 1997-02-26 | 2000-05-02 | Dimera, Llc | Method for reducing coronary artery reactivity |
FR2760639B1 (fr) | 1997-03-14 | 2000-09-22 | Innothera Lab Sa | Association therapeutique mineralo-vitaminique sous forme de preparation unitaire liquide buvable |
US6093394A (en) | 1997-04-11 | 2000-07-25 | Gynelogix, Inc. | Vaginal lactobacillus medicant |
DE19718012C1 (de) | 1997-04-29 | 1998-10-08 | Jenapharm Gmbh | Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe |
IT1291362B1 (it) | 1997-05-13 | 1999-01-07 | Vectorpharma Int | Composizioni farmaceutiche multicomponente bifasiche contenenti sostanze atte a modificare la partizione dei principi attivi |
CN1193718C (zh) | 1997-05-28 | 2005-03-23 | 英特瑞格 | 猪用阴道内器具及其使用方法 |
ATE315931T1 (de) | 1997-06-23 | 2006-02-15 | Cellegy Pharma Inc | Microdosistherapie von gefässbedingten erscheinungen durch no-donoren |
US6039968A (en) | 1997-06-24 | 2000-03-21 | Hoechst Marion Roussel | Intravaginal drug delivery device |
DE19728516C2 (de) | 1997-07-04 | 1999-11-11 | Sanol Arznei Schwarz Gmbh | TTS zur Verabreichung von Levonorgestrel und gegebenenfalls Estradiol |
DE19728517C2 (de) | 1997-07-04 | 1999-11-11 | Sanol Arznei Schwarz Gmbh | TTS zur Verabreichung von Sexualsteroidhormonen und Verfahren zu seiner Herstellung |
US6217886B1 (en) | 1997-07-14 | 2001-04-17 | The Board Of Trustees Of The University Of Illinois | Materials and methods for making improved micelle compositions |
DE19739916C2 (de) | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
US20040234606A1 (en) | 1997-09-12 | 2004-11-25 | Levine Howard L. | Localized vaginal delivery without detrimental blood levels |
US8765177B2 (en) | 1997-09-12 | 2014-07-01 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
GB9720470D0 (en) | 1997-09-25 | 1997-11-26 | Ethical Pharmaceuticals South | Inhibition of crystallization in transdermal devices |
US8257725B2 (en) | 1997-09-26 | 2012-09-04 | Abbott Laboratories | Delivery of highly lipophilic agents via medical devices |
US6201072B1 (en) | 1997-10-03 | 2001-03-13 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
US5968919A (en) | 1997-10-16 | 1999-10-19 | Macrochem Corporation | Hormone replacement therapy drug formulations for topical application to the skin |
US6306914B1 (en) | 1997-10-21 | 2001-10-23 | Columbia Laboratories, Inc. | Progestin therapy for maintaining amenorrhea |
US20040044080A1 (en) | 1997-10-28 | 2004-03-04 | Place Virgil A. | Treatment of dyspareunia with topically administered nitroglycerin formulations |
WO1999021562A1 (en) | 1997-10-28 | 1999-05-06 | Asivi, Llc | Treatment of female sexual dysfunction |
US20020099003A1 (en) | 1997-10-28 | 2002-07-25 | Wilson Leland F. | Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof |
US6193991B1 (en) | 1997-10-29 | 2001-02-27 | Atul J. Shukla | Biodegradable delivery systems of biologically active substances |
EP1030629A4 (en) | 1997-11-03 | 2001-09-05 | Deschutes Medical Products Inc | PESSAR WITH A CARTRIDGE CONTAINING DRUGS |
US6372732B1 (en) | 1997-11-19 | 2002-04-16 | Humanetics Corporation | Use of delta5-androstene-3beta-ol-7, 17-dione in the treatment of lupus erythematosus |
US6692763B1 (en) | 1998-11-19 | 2004-02-17 | The Regents Of The University Of California | Methods for treating postmenopausal women using ultra-low doses of estrogen |
NZ330596A (en) | 1998-06-05 | 2001-02-23 | Dec Res | Intravaginal devices allowing for increased uptake of active ingredients |
US5891868A (en) | 1997-11-21 | 1999-04-06 | Kaiser Foundation Health Plan, Inc. | Methods for treating postmenopausal women using ultra-low doses of estrogen |
US20020031513A1 (en) | 1997-11-24 | 2002-03-14 | Shamir Leibovitz | Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals |
FR2772617B1 (fr) | 1997-12-19 | 2001-03-09 | Besins Iscovesco Lab | Comprime de progesterone et son procede de preparation |
US6030948A (en) | 1997-12-19 | 2000-02-29 | Mann; Morris A. | Hair regeneration compositions for treatment of alopecia and methods of application related thereto |
US6267984B1 (en) | 1997-12-22 | 2001-07-31 | Alza Corporation | Skin permeation enhancer compositions comprising a monoglyceride and ethyl palmitate |
US6503896B1 (en) | 1997-12-24 | 2003-01-07 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
US6054446A (en) | 1997-12-24 | 2000-04-25 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
US6548491B2 (en) | 1997-12-24 | 2003-04-15 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
FR2774291B1 (fr) | 1998-02-03 | 2000-04-21 | Innothera Lab Sa | Specialite pharmaceutique sous forme galenique unitaire de comprimes a croquer ou a sucer, comprenant comme principe actif du fer element |
US6312703B1 (en) | 1998-02-06 | 2001-11-06 | Lecigel, Llc | Compressed lecithin preparations |
IT1298575B1 (it) | 1998-02-06 | 2000-01-12 | Vectorpharma Int | Composizioni farmaceutiche in forma di nanoparticelle comprendenti sostanze lipidiche e sostanze antifiliche e relativo processo di |
US6001846A (en) | 1998-02-17 | 1999-12-14 | Ligand Pharmaceuticals Incorporated | Process for the preparation of 1,2-dihydroquinolines |
US6028057A (en) | 1998-02-19 | 2000-02-22 | Thorn Bioscience, Llc | Regulation of estrus and ovulation in gilts |
DE19807791A1 (de) | 1998-02-19 | 1999-08-26 | Schering Ag | Kombinationspräparat aus Östrogen und Antiöstrogen |
US6287693B1 (en) | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
US20010056068A1 (en) | 1998-03-04 | 2001-12-27 | Kristof Chwalisz | Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives |
FR2775599B1 (fr) | 1998-03-09 | 2001-08-17 | Besins Iscovesco Lab | Composition pharmaceutique a base de progesterone naturelle de synthese et d'oestradiol et son procede de preparation |
FR2776191B1 (fr) | 1998-03-23 | 2002-05-31 | Theramex | Composition hormonale topique a effet systemique |
EP1024808A1 (en) | 1998-04-11 | 2000-08-09 | Errekappa Euroterapici S.p.a. | Pharmaceutical preparations containing hydrosoluble ketoprofen salts and their application |
US20030040790A1 (en) | 1998-04-15 | 2003-02-27 | Furst Joseph G. | Stent coating |
EP2002839A1 (en) | 1998-04-17 | 2008-12-17 | Ortho McNeil Pharmaceutical, Inc. | Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
FR2777783A1 (fr) | 1998-04-24 | 1999-10-29 | Innothera Lab Sa | Association pharmaceutique d'imidazoles pour le traitement local des vulvo-vaginites infectieuses et des vaginoses |
FR2777784B1 (fr) | 1998-04-27 | 2004-03-19 | Arepa | Composition pharmaceutique a base d'estrogene et de progesterone |
US6277418B1 (en) | 1998-06-02 | 2001-08-21 | Baylor College Of Medicine | Corn extract contraceptive |
FR2779438B1 (fr) | 1998-06-03 | 2004-12-24 | Jean Marc Aiache | Gel stable, son procede de preparation, et compositions pharmaceutiques le comprenant |
ES2228044T3 (es) | 1998-06-03 | 2005-04-01 | Jean-Marc Aiache | Mezcla de gel estable en forma de una mezcla de oleogel y gel acuoso. |
DE19825591A1 (de) | 1998-06-09 | 1999-12-23 | Jenapharm Gmbh | Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata |
US6465445B1 (en) | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
NZ330726A (en) | 1998-06-18 | 2000-10-27 | Dec Res | Intra-vaginal delivery unit or composition containing a cyclodextrin which improves absorbtion of 17-beta oestradiol or oestradiol benzoate |
DE19827732A1 (de) | 1998-06-22 | 1999-12-23 | Rottapharm Bv | Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie |
PT1094781E (pt) | 1998-07-07 | 2008-10-08 | Transdermal Technologies Inc | Composições para administração transdérmica rápida e não irritante de agentes farmacologicamente activos e métodos para formulação de tais composições e sua administração |
US6294188B1 (en) | 1998-07-09 | 2001-09-25 | Aviana Biopharm Inc. | Methods involving changing the constitutive and stimulated secretions of the local reproductive system of women |
US6124362A (en) | 1998-07-17 | 2000-09-26 | The Procter & Gamble Company | Method for regulating hair growth |
DE19834931A1 (de) | 1998-07-28 | 2000-02-24 | Jenapharm Gmbh | Verwendung von biogenen Estrogenen zur Hormonsubstitutionstherapie |
DE19834007C1 (de) | 1998-07-29 | 2000-02-24 | Lohmann Therapie Syst Lts | Estradiolhaltiges Pflaster zur transdermalen Applikation von Hormonen und seine Verwendung |
US20070015698A1 (en) | 1998-07-30 | 2007-01-18 | United States Of America As Represented By The Secretary Of Health | Treatment of skin, and wound repair, with thymosin beta 4 |
US20030181353A1 (en) | 1998-08-03 | 2003-09-25 | Nyce Jonathan W. | Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia |
ATE315033T1 (de) | 1998-08-07 | 2006-02-15 | Chiron Corp | Subtituierte isoxazole derivate als estrogen rezeptor modulatore |
AU5675099A (en) | 1998-08-17 | 2000-03-06 | William E. Trout | Use of zeranol to modulate reproductive cycles |
US8257724B2 (en) | 1998-09-24 | 2012-09-04 | Abbott Laboratories | Delivery of highly lipophilic agents via medical devices |
US20020169205A1 (en) | 1998-09-29 | 2002-11-14 | Krzysztof Chwalisz | Implantation rates after in vitro fertilization, and treatment of infertility and early pregnancy loss with a nitric oxide donor or substrate alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors in combination with antiprogestins or other agents |
WO2000019978A2 (en) | 1998-10-05 | 2000-04-13 | The Penn State Research Foundation | Compositions and methods for enhancing receptor-mediated cellular internalization |
JP4399044B2 (ja) | 1998-10-14 | 2010-01-13 | 久光製薬株式会社 | 吸収促進剤及び該吸収促進剤を有してなる経皮吸収製剤 |
US6372246B1 (en) | 1998-12-16 | 2002-04-16 | Ortho-Mcneil Pharmaceutical, Inc. | Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals |
US20040120891A1 (en) | 1998-12-21 | 2004-06-24 | Craig Hill | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
EP1140021B1 (en) | 1998-12-23 | 2004-08-04 | Idea Ag | Improved formulation for topical non-invasive application in vivo |
GB9828480D0 (en) | 1998-12-24 | 1999-02-17 | Dermatech Limited | Transdermal drug delivery system |
US6117446A (en) | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
JP2002536319A (ja) | 1999-02-05 | 2002-10-29 | シプラ・リミテッド | 局所用スプレー |
US7919109B2 (en) | 1999-02-08 | 2011-04-05 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
US6080118A (en) | 1999-02-25 | 2000-06-27 | Blythe; Cleveland | Vaginal probe and method of using same |
US20030104048A1 (en) | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
DE19911799A1 (de) | 1999-03-17 | 2000-09-28 | Lohmann Therapie Syst Lts | Sammelpackung zur Entnahme von befüllten Beuteln in vorgebener Reihenfolge |
CA2267743C (en) | 1999-03-30 | 2011-07-26 | Robert F. Casper | Low dose estrogen interrupted hormone replacement therapy |
US6287588B1 (en) | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
US6451300B1 (en) | 1999-05-03 | 2002-09-17 | The Procter & Gamble Company | Anti-dandruff and conditioning shampoos containing polyalkylene glycols and cationic polymers |
US6974569B2 (en) | 1999-05-03 | 2005-12-13 | The Procter & Gamble Company | Shampoos providing a superior combination anti-dandruff efficacy and condition |
US6649155B1 (en) | 1999-05-03 | 2003-11-18 | The Procter & Gamble Company | Anti-dandruff and conditioning shampoos containing certain cationic polymers |
KR20020011985A (ko) | 1999-05-07 | 2002-02-09 | 파르마솔 게엠베하 | 액상 및 고체상 지질 혼합물에 기초한 지질입자들 및 그의제조방법 |
KR100663684B1 (ko) | 1999-05-13 | 2007-01-02 | 히사미쓰 세이야꾸 가부시키가이샤 | 부착제 |
US6962691B1 (en) | 1999-05-20 | 2005-11-08 | U & I Pharmaceuticals Ltd. | Topical spray compositions |
US6645947B1 (en) | 1999-05-20 | 2003-11-11 | Chitogenics, Inc. | Adhesive N, O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins |
US7919119B2 (en) | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
NZ530701A (en) | 1999-06-04 | 2005-09-30 | Alza Corp | Implantable gel compositions comprising compressed particles including the active agent in a bioerodible gel |
US6465004B1 (en) | 1999-06-05 | 2002-10-15 | Noven Pharmaceuticals, Inc. | Solubility enhancement of drugs in transdermal drug delivery systems and methods of use |
BR0011740A (pt) | 1999-06-11 | 2002-05-14 | Watson Pharmaceuticals Inc | Administração de esteróides androgênicos não-orais a mulheres |
GB9914648D0 (en) | 1999-06-24 | 1999-08-25 | Univ Birmingham | Control of infra-ocular pressure |
US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US6303132B1 (en) | 1999-07-16 | 2001-10-16 | Ardell H. Nelson | Administering progesterone using EMU oil |
KR20010010393A (ko) | 1999-07-20 | 2001-02-05 | 김윤 | 소수성 고분자와 친수성 고분자의 생분해성 블록 공중합체 및이를 포함하는 약물 전달체 조성물 |
NZ337318A (en) | 1999-08-18 | 2002-07-26 | Interag | Dispensing apparatus for dispensing same or different materials for at least two reservoirs |
US20010036481A1 (en) | 1999-08-25 | 2001-11-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
AU6938600A (en) | 1999-08-26 | 2001-03-19 | West Virginia University | Cervical agent delivery system |
RU2449796C9 (ru) | 1999-08-31 | 2007-10-27 | Shering Aktsiengezell Shaft | Фармацевтическая комбинация этинилэстрадиола и дроспиренона для использования в качестве контрацептива |
US6787531B1 (en) | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
JP2003532629A (ja) | 1999-09-08 | 2003-11-05 | ワトソン ファーマシューティカルズ, インコーポレイテッド | 第4アンモニウム塩の経皮薬剤放出への使用 |
US6610674B1 (en) | 1999-09-28 | 2003-08-26 | University Of Pennsylvania | Method of treating inflammatory conditions with progesterone analogs |
US6479545B1 (en) | 1999-09-30 | 2002-11-12 | Drugtech Corporation | Formulation for menopausal women |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
US6436633B1 (en) | 1999-10-22 | 2002-08-20 | The Pennsylvania State University | Human xenografts for microbicide testing and anatomical modeling |
US6958327B1 (en) | 1999-11-02 | 2005-10-25 | Schering, Ag | 18 Norsteroids as selectively active estrogens |
US20030180352A1 (en) | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
AUPQ419099A0 (en) | 1999-11-23 | 1999-12-16 | Ko, Thomas Sai Ying | Novel compositions and methods |
US7384650B2 (en) | 1999-11-24 | 2008-06-10 | Agile Therapeutics, Inc. | Skin permeation enhancement composition for transdermal hormone delivery system |
US20020012710A1 (en) | 1999-11-29 | 2002-01-31 | Rimonest Ltd. | Pomegranate products useful in improving health and methods of use thereof |
US6708822B1 (en) | 1999-11-30 | 2004-03-23 | Cutispharma, Inc. | Compositions and kits for compounding pharmaceuticals |
US20040191276A1 (en) | 1999-11-30 | 2004-09-30 | Cutispharma, Inc. | Compositions and kits for compounding pharmaceuticals |
US6562370B2 (en) | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers |
US20010032125A1 (en) | 1999-12-20 | 2001-10-18 | Sundeep Bhan | Activation of coupons based on quiz or questionnaire |
US6544553B1 (en) | 1999-12-28 | 2003-04-08 | Watson Pharmaceuticals, Inc. | Dosage forms and methods for oral delivery of progesterone |
US6967023B1 (en) | 2000-01-10 | 2005-11-22 | Foamix, Ltd. | Pharmaceutical and cosmetic carrier or composition for topical application |
GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
US7335650B2 (en) | 2000-01-14 | 2008-02-26 | Sterix Limited | Composition |
US6653298B2 (en) | 2000-01-14 | 2003-11-25 | Sterix Limited | Composition |
US20020132801A1 (en) | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
AU3104301A (en) | 2000-01-20 | 2001-07-31 | Noven Pharmaceuticals, Inc. | Compositions and methods to effect the release profile in the transdermal administration of active agents |
EP1251855A1 (en) | 2000-01-28 | 2002-10-30 | Endorecherche, Inc. | Selective estrogen receptor modulators in combination with estrogens |
FR2804603B1 (fr) | 2000-02-04 | 2004-01-23 | Rhodia Chimie Sa | Procede continu pour formuler sous forme de granules une ou plusieurs matieres actives pharmaceutiques |
US6562790B2 (en) | 2000-02-05 | 2003-05-13 | Chein Edmund Y M | Hormone therapy methods and hormone products for abating coronary artery blockage |
KR20080049148A (ko) | 2000-02-16 | 2008-06-03 | 벤트레이 파마슈티칼스, 인코포레이티드 | 약학적 조성물 |
WO2001062237A2 (en) | 2000-02-23 | 2001-08-30 | Orentreich Foundation For The Advancement Of Science, Inc. | Compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus |
US6660726B2 (en) | 2000-03-10 | 2003-12-09 | Endeavor Pharmaceuticals | Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same |
US6855703B1 (en) | 2000-03-10 | 2005-02-15 | Endeavor Pharmaceuticals | Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds |
US7459445B2 (en) | 2000-03-10 | 2008-12-02 | Duramed Pharmaceuticals, Inc. | Estrogenic compounds and topical pharmaceutical formulations of the same |
US7989436B2 (en) | 2003-07-23 | 2011-08-02 | Duramed Pharmaceuticals, Inc. | Estrogenic compounds and pharmaceutical formulations comprising the same |
US20010034340A1 (en) | 2000-03-20 | 2001-10-25 | American Home Products Corporation | Hormone replacement therapy |
US20040176336A1 (en) | 2000-03-21 | 2004-09-09 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
BR0109603A (pt) | 2000-03-27 | 2004-02-25 | Schott Glas | Novas composições cosméticas, de higiene pessoal, agente de limpeza e de suplemento nutricional e métodos para fabricar e utilizar as mesmas |
IL135335A (en) | 2000-03-29 | 2013-12-31 | Lycored Natural Prod Ind Ltd | Use of Carotenoids in Preparing Pharmaceuticals to Prevent Adverse Effects from Hormones and Pharmaceuticals Containing Carotenoids |
AU4966101A (en) | 2000-03-31 | 2001-10-15 | Us Gov Health & Human Serv | Methods of making and using 7alpha,11beta-dimethyl-17beta-hydroxy-4-estren-3-one17beta-trans-4-m-butylcyclohexane carboxylate and 7alpha,11beta-dimethyl-17beta -hydroxyestr-4-en-3-one 17-undecanoate |
EE200200589A (et) | 2000-04-12 | 2004-04-15 | Schering Aktiengesellschaft | 8ß-hüdrokarbüülasendatud östratrieenid kasutamiseks selektiivsete östrogeenidena |
US20020013327A1 (en) | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
US7758888B2 (en) | 2000-04-21 | 2010-07-20 | Sol-Gel Technologies Ltd. | Composition exhibiting enhanced formulation stability and delivery of topical active ingredients |
US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
US7018645B1 (en) | 2000-04-27 | 2006-03-28 | Macromed, Inc. | Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties |
US8119138B2 (en) | 2000-05-10 | 2012-02-21 | Signe Biopharma Inc. | Anti-estrogen and immune modulator combinations for treating breast cancer |
US6495534B2 (en) | 2000-05-15 | 2002-12-17 | Pharmacia & Upjohn Spa | Stabilized aqueous suspensions for parenteral use |
KR100452972B1 (ko) | 2000-05-16 | 2004-10-14 | 주식회사 삼양사 | 경피투여용 하이드로젤 조성물 |
CN1431906A (zh) | 2000-05-31 | 2003-07-23 | 日绊株式会社 | 透皮吸收型甾体外用药 |
GB0015617D0 (en) | 2000-06-26 | 2000-08-16 | Vectura Ltd | Improved preparations for dermal delivery of active substances |
US7001911B2 (en) | 2000-06-28 | 2006-02-21 | Bristol-Myers Squibb Company | Fused cyclic modulators of nuclear hormone receptor function |
US20030114420A1 (en) | 2000-06-28 | 2003-06-19 | Salvati Mark E. | Fused cyclic modulators of nuclear hormone receptor function |
US20040077605A1 (en) | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
US6740333B2 (en) | 2000-07-07 | 2004-05-25 | Anestic Aps | Suppository and composition comprising at least one polyethylene glycol |
US6420352B1 (en) | 2000-07-19 | 2002-07-16 | W. Roy Knowles | Hair loss prevention |
JP2004504342A (ja) | 2000-07-24 | 2004-02-12 | ファルマシア・アンド・アップジョン・カンパニー | 極めて水不溶性の脂肪親和性薬剤用の自己乳化性ドラッグデリバリーシステム |
US20020119174A1 (en) | 2000-07-26 | 2002-08-29 | Gardlik John Michael | Compositions useful for regulating hair growth containing metal complexes of oxidized carbohydrates |
US20020035070A1 (en) | 2000-07-26 | 2002-03-21 | The Procter & Gamble Company | Method of regulating hair growth using metal complexes of oxidized carbohydrates |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
AU8206401A (en) | 2000-08-03 | 2002-02-18 | Antares Pharma Ipl Ag | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
US20040198706A1 (en) | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
US7163681B2 (en) | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
GB0021317D0 (en) | 2000-08-30 | 2000-10-18 | Queen Mary & Westfield College | Transdermal pharmaceutical delivery composition |
US20040092494A9 (en) | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
DE10045380A1 (de) | 2000-09-14 | 2002-04-04 | Schering Ag | Verfahren zur Kontrazeption und dessen Darreichungsform |
FR2814074B1 (fr) | 2000-09-15 | 2003-03-07 | Theramex | Nouvelles compositions estro-progestatives topiques a effet systemique |
AU2001269943B2 (en) | 2000-09-19 | 2006-11-09 | Bristol-Myers Squibb Company | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
EE200300109A (et) | 2000-09-20 | 2005-04-15 | Nycomed Pharma As | Protsess vedela emulsioonkompositsiooni valmistamiseks ja emulsiooni kontsentraadi valmistamiseks, farmatseutiline kompositsioon, emulsiooni kontsentraat, komplekt ja emulsioonkompositsioon |
US20020119187A1 (en) | 2000-09-29 | 2002-08-29 | Cantor Adam S. | Composition for the transdermal delivery of fentanyl |
US20040039356A1 (en) | 2000-10-16 | 2004-02-26 | Masayoshi Maki | Compositions for external preparations |
US6635274B1 (en) | 2000-10-27 | 2003-10-21 | Biochemics, Inc. | Solution-based transdermal drug delivery system |
CA2427731A1 (en) | 2000-10-30 | 2002-05-10 | University Of Zurich | Gnrh analogues for treatment of urinary incontinence |
US6328987B1 (en) | 2000-11-03 | 2001-12-11 | Jan Marini Skin Research, Inc. | Cosmetic skin care compositions containing alpha interferon |
US20030113268A1 (en) | 2000-11-10 | 2003-06-19 | Mina Buenafae | Degradation-resistant glucocorticosteroid formulations |
US6605605B2 (en) | 2000-11-13 | 2003-08-12 | Milton Hammerly | Estrogenic substances combined with cruciferous indole compounds |
US6682757B1 (en) | 2000-11-16 | 2004-01-27 | Euro-Celtique, S.A. | Titratable dosage transdermal delivery system |
FR2816838B1 (fr) | 2000-11-17 | 2004-12-03 | Oreal | Utilisation de derives de l'acide 2-oxothiazolidine- 4-carboxylique comme agents prodesquamants |
HUP0301892A3 (en) | 2000-11-17 | 2005-06-28 | Warner Lambert Company Llc Mor | Pharmaceutical compositions for treatment of sexual dysfunction and their preparation |
AUPR184500A0 (en) | 2000-12-01 | 2001-01-04 | Drug Delivery Solutions Pty Ltd | Dispensing device |
US6743448B2 (en) | 2000-12-11 | 2004-06-01 | Abraham H. Kryger | Topical testosterone formulations and associated methods |
DK1361881T3 (da) | 2000-12-14 | 2006-02-20 | Ortho Mcneil Pharm Inc | Steroide hormonprodukter og fremgangsmåder til fremstilling heraf |
US7018992B2 (en) | 2000-12-15 | 2006-03-28 | Novo Nordisk A/S | Hormone composition |
EP1216712A1 (en) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Cyclodextrin-drospirenone inclusion complexes |
EP1216699A1 (de) | 2000-12-21 | 2002-06-26 | Schering Aktiengesellschaft | Transdermalsystem enthaltend ein hochpotentes Gestagen |
US20020151530A1 (en) | 2000-12-22 | 2002-10-17 | Leonard Thomas W. | Method of treating hormonal deficiencies in women undergoing estrogen replacement therapy |
US20020107230A1 (en) | 2000-12-22 | 2002-08-08 | Waldon R. Forrest | Methods and formulations for the treatment of female sexual dysfunction |
FR2818905A1 (fr) | 2000-12-28 | 2002-07-05 | Cll Pharma | Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile |
WO2002053138A2 (en) | 2001-01-02 | 2002-07-11 | Elisabeth Shanahan-Prendergast | Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens |
US20020197286A1 (en) | 2001-01-16 | 2002-12-26 | Jane Brandman | Method for preventing and treating skin aging |
FR2820320B1 (fr) | 2001-02-02 | 2003-04-04 | Oreal | Suspension de nanospheres de principe actif lipophile stabilisee par des polymeres hydrodispersibles |
AU2002240312A1 (en) | 2001-02-08 | 2002-08-19 | Pankaj Paranjp | Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates |
US7381427B2 (en) | 2001-02-09 | 2008-06-03 | Mickey Miller | Seborrheic keratosis treatment |
NZ509894A (en) | 2001-02-09 | 2002-11-26 | Interag | A "T" or "Y" shaped intravaginal device suitable for delivery of pharmaceuticals such as progesterone |
US7303763B2 (en) | 2001-02-12 | 2007-12-04 | Watson Laboratories, Inc. | Compositions for conjugated estrogens and associated methods |
US20040087548A1 (en) | 2001-02-27 | 2004-05-06 | Salvati Mark E. | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
DE60217835D1 (en) | 2001-02-28 | 2007-03-15 | John H Griffin | Plasmaglucosylceramiddefizienz als risikofaktor für thrombose und modulator von anticoagulant protein c |
FR2821555B1 (fr) | 2001-03-01 | 2003-05-16 | Besins Int Lab | Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations |
WO2002069906A2 (en) | 2001-03-06 | 2002-09-12 | Cellegy Pharmaceuticals, Inc. | Compounds and methods for the treatment of urogenital disorders |
CN1555266A (zh) | 2001-03-16 | 2004-12-15 | 激素替代疗法 | |
FR2828102B1 (fr) | 2001-03-28 | 2004-07-09 | Ifc Sa | Utilisation des lipoaminoacides dans une composition pharmaceutique comme promoteur et systeme disperse a usage pharmaceutique contenant de tels composes |
EP1385459A2 (en) | 2001-03-30 | 2004-02-04 | Elan Pharmaceuticals, Inc. | Transdermal delivery of pergolide |
WO2002078604A2 (en) | 2001-03-30 | 2002-10-10 | Elan Transdermal Technologies, Inc. | Transdermal delivery of bioactive material |
US20020142941A1 (en) | 2001-03-30 | 2002-10-03 | Pro Duct Health, Inc. | Intraductal treatment targeting methylated promoters in breast cancer |
US20040131670A1 (en) | 2001-04-17 | 2004-07-08 | Ping Gao | Pellicle-resistant gelatin capsule |
US6860859B2 (en) | 2001-04-20 | 2005-03-01 | Monsanto Technology Llc | Apparatus and method for detection of estrus and/or non-pregnancy |
AU2002256359A1 (en) | 2001-04-24 | 2002-11-05 | Epigenesis Pharmaceuticals, Inc. | Antisense and anti-inflammatory based compositions to treat respiratory disorders |
US6936599B2 (en) | 2001-04-25 | 2005-08-30 | The Regents Of The University Of California | Estriol therapy for multiple sclerosis and other autoimmune diseases |
US20050209208A1 (en) | 2001-04-25 | 2005-09-22 | The Regents Of The University Of California | Use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune disorders |
US8658627B2 (en) | 2001-04-25 | 2014-02-25 | The Regents Of The University Of California | Pregnancy hormone combination for treatment of autoimmune diseases |
US20120322779A9 (en) | 2001-04-25 | 2012-12-20 | Rhonda Voskuhl | Estriol Therapy for Autoimmune and Neurodegenerative Diseases and Disorders |
EP1390038A2 (en) | 2001-05-16 | 2004-02-25 | Endeavor Pharmaceuticals | Treatment of conditions relating to hormone deficiencies by administration of progestins |
DE60217324T2 (de) | 2001-05-18 | 2007-04-26 | Pantarhei Bioscience B.V. | Pharmazeutische zusammensetzung für die hormonersatztherapie |
JP4865958B2 (ja) | 2001-05-23 | 2012-02-01 | 株式会社トクホン | 鎮痛抗炎症局所作用型の貼付剤 |
US20020193356A1 (en) | 2001-05-23 | 2002-12-19 | Van Beek Agatha Antonia Magdalena | Means and method for hormonal contraception |
FR2825277B1 (fr) | 2001-05-30 | 2004-10-15 | Oreal | Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd |
US20020193758A1 (en) | 2001-06-18 | 2002-12-19 | Sca Hygiene Products Ab | Product |
NZ530227A (en) | 2001-06-18 | 2006-09-29 | Noven Pharma | Enhanced drug delivery in transdermal systems |
EP1411922A1 (en) | 2001-07-31 | 2004-04-28 | Pfizer Products Inc. | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
US7094228B2 (en) | 2001-07-31 | 2006-08-22 | Zars, Inc. | Methods and formulations for photodynamic therapy |
DE10141652B4 (de) | 2001-08-24 | 2011-04-07 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung |
ATE429947T1 (de) | 2001-08-29 | 2009-05-15 | Pharmakodex Ltd | Vorrichtung zur topischen verabreichung |
US6911438B2 (en) | 2001-09-12 | 2005-06-28 | Jonathan V. Wright | Hormone replacement formulation |
DE10146541A1 (de) | 2001-09-21 | 2003-04-17 | Kade Pharma Fab Gmbh | Arzneimittel auf Basis von Gestagenen zur dermalen Anwendung |
US7393696B2 (en) | 2001-09-28 | 2008-07-01 | Aspenbio Pharma, Inc. | Bovine pregnancy test |
DE10294402D2 (de) | 2001-09-29 | 2004-11-11 | Solvay Pharm Gmbh | Estrogen-Gestagen Kombinationspräparat und Anwendung |
US20030175329A1 (en) | 2001-10-04 | 2003-09-18 | Cellegy Pharmaceuticals, Inc. | Semisolid topical hormonal compositions and methods for treatment |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
AR026386A1 (es) | 2001-10-24 | 2003-02-12 | Massara Julio Eduardo | Un dispositivo intravaginal que contiene progesterona, util como inductor de celo en bovinos productores de carne y leche, y el procedimiento paraprepararlo |
US7815936B2 (en) | 2001-10-30 | 2010-10-19 | Evonik Degussa Gmbh | Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions |
FR2832065B1 (fr) | 2001-11-13 | 2004-11-05 | Besins Int Belgique | Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations |
US20070196415A1 (en) | 2002-11-14 | 2007-08-23 | Guohua Chen | Depot compositions with multiple drug release rate controls and uses thereof |
PT1446128E (pt) | 2001-11-15 | 2007-03-30 | Pantarhei Bioscience Bv | Utilização de compostos estrogénicos combinados com compostos progestagénicos na terapia hormonal de substituição |
PT1443966E (pt) | 2001-11-15 | 2007-06-21 | Pantarhei Bioscience Bv | Método para a prevenção ou tratamento das doenças ginecológicas benignas |
EP1458361A4 (en) | 2001-11-20 | 2007-04-25 | Advanced Inhalation Res Inc | COMPOSITIONS FOR DISTRIBUTING PRODUCTS WITH LASTING EFFECT |
FR2832311B1 (fr) | 2001-11-21 | 2004-04-16 | Besins Int Belgique | Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations |
US20040022820A1 (en) | 2001-11-28 | 2004-02-05 | David Anderson | Reversed liquid crystalline phases with non-paraffin hydrophobes |
DE10159120B4 (de) | 2001-12-01 | 2006-08-17 | Lts Lohmann Therapie-Systeme Ag | Steroidhormonhaltige transdermale therapeutische Systeme enthaltend Propylenglycolmonocaprylat und seine Verwendung |
AU2002353118A1 (en) | 2001-12-11 | 2003-07-24 | Dor Biopharma, Inc. | Lipid particles and suspensions and uses thereof |
ES2188426B1 (es) | 2001-12-12 | 2004-11-16 | Rosalia Pidal Fernandez | Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias. |
TWI332400B (en) | 2001-12-14 | 2010-11-01 | Solvay Pharm Gmbh | Preformulation for the tableting of natural mixtures of conjugated estrogens |
US7329654B2 (en) | 2001-12-19 | 2008-02-12 | Janssen Pharmaceutica N.V. | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators |
JP4434740B2 (ja) | 2001-12-19 | 2010-03-17 | ブリストル−マイヤーズ スクイブ カンパニー | 核ホルモン受容体機能の調節剤である、縮合ヘテロ環化合物およびその類似体 |
US6962908B2 (en) | 2001-12-21 | 2005-11-08 | Warner Chilcott Company Inc. | Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
WO2003055468A1 (en) | 2001-12-21 | 2003-07-10 | Shire Laboratories Inc. | Oral capsule formulation with increased physical stability |
FR2834212B1 (fr) | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
US6878518B2 (en) | 2002-01-22 | 2005-04-12 | The Trustees Of The University Of Pennsylvania | Methods for determining steroid responsiveness |
US6901278B1 (en) | 2002-01-29 | 2005-05-31 | Morris Notelovitz | Methods for reducing the risk of breast cancer in and improving the health of women |
EA011488B1 (ru) | 2002-02-01 | 2009-04-28 | Ариад Джин Терапьютикс, Инк. | Фосфорсодержащие соединения и их получение |
EP1474069A1 (en) | 2002-02-08 | 2004-11-10 | Advanced Animal Technology Limited | Control of a biological function |
NZ517094A (en) | 2002-02-08 | 2005-03-24 | Advanced Animal Technology Ltd | Improvements in and relating to substance delivery device |
GB0203276D0 (en) | 2002-02-12 | 2002-03-27 | Novartis Ag | Organic compounds |
WO2003068934A2 (en) | 2002-02-14 | 2003-08-21 | Rutter William J | Chimeric molecules for cleavage in a treated host |
DE10206390A1 (de) | 2002-02-15 | 2003-08-28 | Bionorica Ag | Verwendung von selektiv den Estrogenrezeptor beta modulierenden phytoestrogenhaltigen Extrakten |
ATE341333T1 (de) | 2002-02-21 | 2006-10-15 | Schering Ag | Pharmazeutische zusammensetzung, enthaltend ein oder mehrere steroide, eine oder mehrere tetrahydrofolatverbindungen und vitamin b12 |
US20030175333A1 (en) | 2002-03-06 | 2003-09-18 | Adi Shefer | Invisible patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin |
US7741116B2 (en) | 2002-03-06 | 2010-06-22 | University Of Cincinnati | Surgical device for skin therapy or testing |
AU2003222273A1 (en) | 2002-03-11 | 2003-09-29 | Janssen Pharmaceutica N.V. | Sulfatase inhibiting progestogen-only contraceptive regimens |
US20030225048A1 (en) | 2002-03-11 | 2003-12-04 | Caubel Patrick Michel | Sulfatase inhibiting continuous progestogen contraceptive regimens |
PT1482948E (pt) | 2002-03-11 | 2006-11-30 | Janssen Pharmaceutica Nv | Terapia de substituição hormonal contínua com progestogénio inibidor de sulfatase |
PL372490A1 (en) | 2002-03-11 | 2005-07-25 | Schering Aktiengesellschaft | 5-{2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino}-phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy |
JP2005526083A (ja) * | 2002-03-14 | 2005-09-02 | ワトソン ファーマシューティカルズ, インコーポレイテッド | プロゲステロンの経口薬物送達システム |
DE10211832A1 (de) | 2002-03-16 | 2003-10-02 | Lohmann Therapie Syst Lts | Hormonhaltiges transdermales therapeutisches System mit einem Wirkstoffreservoir auf der Basis von Vinylacetat-Vinylpyrrolidon-Copolymer mit verbesserter Kohäsion |
FR2837100B1 (fr) | 2002-03-18 | 2004-07-23 | Flamel Tech Sa | Comprimes a bases de microcapsules a liberation modifiee |
DK1487416T3 (da) | 2002-03-26 | 2010-03-29 | Teva Pharma | Lægemiddelmikropartikler |
US7300926B2 (en) | 2002-04-01 | 2007-11-27 | University Of Florida Research Foundation, Inc. | Steroidal quinols and their use for estrogen replacement therapy |
US20040235812A1 (en) | 2002-04-03 | 2004-11-25 | Caspers Robert F | Pharmaceutical composition comprisng an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male |
US20030191096A1 (en) | 2002-04-03 | 2003-10-09 | Leonard Thomas W. | Method of hormonal therapy |
IL164163A0 (en) | 2002-04-09 | 2005-12-18 | Pharmacia Corp | Process for preparing a finely self-emulsifiable pharmaceutical composition |
US6750291B2 (en) | 2002-04-12 | 2004-06-15 | Pacific Corporation | Film-forming agent for drug delivery and preparation for percutaneous administration containing the same |
US20050214384A1 (en) | 2002-04-23 | 2005-09-29 | Vijaya Juturu | Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance |
DE10218109A1 (de) * | 2002-04-23 | 2003-11-20 | Jenapharm Gmbh | Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen |
IL164808A0 (en) | 2002-04-26 | 2005-12-18 | Schering Ag | Treatment of hypertesion in women receiving hormone replacement therapy |
WO2003092588A2 (en) | 2002-04-30 | 2003-11-13 | Merck & Co., Inc. | 4-azasteroid derivatives as androgen receptor modulators |
JP2005525403A (ja) | 2002-05-03 | 2005-08-25 | ピーアール ファーマシューティカルズ, インコーポレイテッド | エストラジオール代謝産物の徐放性組成物 |
US7727720B2 (en) | 2002-05-08 | 2010-06-01 | Ravgen, Inc. | Methods for detection of genetic disorders |
US8591951B2 (en) | 2002-05-15 | 2013-11-26 | Joachim B. Kohn | Tri-block copolymers for nanosphere-based drug delivery |
US6821524B2 (en) | 2002-06-03 | 2004-11-23 | Jan Marini Skin Research, Inc. | Cosmetic skin care compositions |
US6943021B2 (en) | 2002-06-07 | 2005-09-13 | Mattek Corporation | Three dimensional vaginal tissue model containing immune cells |
CA2489270C (en) | 2002-06-11 | 2012-08-07 | Pantarhei Bioscience B.V. | A method of treating human skin and a skin care composition for use in such a method |
US7414043B2 (en) | 2002-06-11 | 2008-08-19 | Schering Ag | 9-α-substituted estratrienes as selectively active estrogens |
US20040048900A1 (en) | 2002-06-17 | 2004-03-11 | Pamela Flood | Nicotine and/or nicotine agonists for the treatment of general anesthetic effects and side effects |
FR2841138B1 (fr) | 2002-06-25 | 2005-02-25 | Cll Pharma | Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation |
US20050186141A1 (en) | 2002-06-25 | 2005-08-25 | Acrux Dds Pty Ltd. | Transdermal aerosol compositions |
KR100533458B1 (ko) | 2002-07-20 | 2005-12-07 | 대화제약 주식회사 | 파클리탁셀의 가용화용 조성물 및 그의 제조 방법 |
WO2004011008A1 (de) | 2002-07-25 | 2004-02-05 | Schering Aktiengesellschaft | ZUSAMMENSETZUNG, ENTHALTEND EIN ANDROGENES 11β-HALOGENSTEROID UND EIN GESTAGEN SOWIE MÄNNLICHES KONTRAZEPTIVUM AUF BASIS DIESER ZUSAMMENSETZUNG |
US6960337B2 (en) | 2002-08-02 | 2005-11-01 | Balance Pharmaceuticals, Inc. | Methods and compositions for treating benign gynecological disorders |
US8268352B2 (en) | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
TR200201966A2 (tr) | 2002-08-07 | 2004-02-23 | Edko Pazarlama Tanitim Ti̇caret Li̇mi̇ted Şi̇rketi̇ | Farmasötik terkip. |
AU2002950713A0 (en) | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
US20030049307A1 (en) | 2002-08-15 | 2003-03-13 | Gyurik Robert J. | Pharmaceutical composition |
DE60330679D1 (de) | 2002-08-20 | 2010-02-04 | Univ Singapore | Phytoprogestogenen extrakten aus rhizoma ligusticum chuanxiong und ihre verwendungszwecke |
PT1539184E (pt) | 2002-08-28 | 2007-02-28 | Robert Casper | Regímen de substituição de estrogénio |
AU2003278766A1 (en) | 2002-09-04 | 2004-03-29 | Microchips, Inc. | Method and device for the controlled delivery of parathyroid hormone |
ATE452641T1 (de) | 2002-09-05 | 2010-01-15 | Pantarhei Bioscience Bv | Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate |
US6967194B1 (en) | 2002-09-18 | 2005-11-22 | Susan Matsuo | Bio-identical hormones and method of use |
GB0222522D0 (en) | 2002-09-27 | 2002-11-06 | Controlled Therapeutics Sct | Water-swellable polymers |
US20040062794A1 (en) | 2002-09-30 | 2004-04-01 | Lee Shulman | 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy |
EP1556061B1 (en) | 2002-10-04 | 2007-04-18 | Photokinetix Inc | Photokinetic delivery of biologically active substances using pulsed incoherent light |
DE10247399A1 (de) | 2002-10-08 | 2004-04-29 | Schering Ag | Pharmazeutische Zubereitungen, Verwendung dieser Zubereitung und Verfahren zur Erhöhung der Bioverfügbarkeit von peroral zu applizierenden Arzneistoffen |
FR2845597B1 (fr) | 2002-10-11 | 2005-03-11 | Innothera Lab Sa | Formulation orale seche contenant de la diosmine sous forme pharmaceutique de comprime a croquer |
US20040146894A1 (en) | 2002-10-14 | 2004-07-29 | Warrington Janet A. | Methods of diagnosing and treating stress urinary incontinence |
GB0224415D0 (en) | 2002-10-21 | 2002-11-27 | Medical Res Council | Compositions |
AU2003274823A1 (en) | 2002-10-23 | 2004-05-13 | Pantarhei Bioscience B.V. | Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
US20060018937A1 (en) | 2002-10-25 | 2006-01-26 | Foamix Ltd. | Steroid kit and foamable composition and uses thereof |
US20080206161A1 (en) | 2002-10-25 | 2008-08-28 | Dov Tamarkin | Quiescent foamable compositions, steroids, kits and uses thereof |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US20060193789A1 (en) | 2002-10-25 | 2006-08-31 | Foamix Ltd. | Film forming foamable composition |
US20070292461A1 (en) | 2003-08-04 | 2007-12-20 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
BR0314916A (pt) | 2002-10-25 | 2005-08-16 | Foamix Ltd | Espuma farmacêutica e cosmética |
US20070292359A1 (en) | 2002-10-25 | 2007-12-20 | Foamix Ltd. | Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof |
DE10249853A1 (de) | 2002-10-25 | 2004-05-13 | Liedtke, Rainer K., Dr. | Pflasterartige Chip-Systeme zur thermodynamischen Kontrolle topisch dermaler und transdermaler Systeme |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
WO2004037843A2 (en) | 2002-10-25 | 2004-05-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments |
US20040087564A1 (en) | 2002-10-31 | 2004-05-06 | Wright D. Craig | Delivery composition and method |
US20040138103A1 (en) | 2002-11-07 | 2004-07-15 | Procyte Corporation | Compositions containing peptide copper complexes and metalloproteinase inhibitors and methods related thereto |
US20040093261A1 (en) | 2002-11-08 | 2004-05-13 | Vivek Jain | Automatic validation of survey results |
US20040089308A1 (en) | 2002-11-13 | 2004-05-13 | Welch Robert A. | Cervical ring to deliver medication |
US20040097468A1 (en) | 2002-11-20 | 2004-05-20 | Wimalawansa Sunil J. | Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment |
US7674783B2 (en) | 2002-11-22 | 2010-03-09 | Dimera Inc. | Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease |
WO2004050057A2 (en) | 2002-12-04 | 2004-06-17 | Technologies Biolactis Inc. | An exopolysaccharides delivery system for active molecules |
FR2848112B1 (fr) | 2002-12-10 | 2007-02-16 | Besins Int Belgique | Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant au moins un progestatif et/ou au moins un oestrogene, son procede de preparation et ses utilisations |
US20040115226A1 (en) | 2002-12-12 | 2004-06-17 | Wenji Li | Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same |
EP1428526A1 (en) | 2002-12-13 | 2004-06-16 | Rijksuniversiteit Groningen | Formulation for fast dissolution of lipophilic compounds |
US20040115287A1 (en) | 2002-12-17 | 2004-06-17 | Lipocine, Inc. | Hydrophobic active agent compositions and methods |
GEP20074224B (en) | 2002-12-18 | 2007-10-25 | Ferrer Int | Pharmaceutical compositions of sertaconazole for vaginal use |
US20040121003A1 (en) | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
FR2849380A1 (fr) | 2002-12-27 | 2004-07-02 | Ernest Loumaye | NOUVELLE UTILISATION D'UN AGONISTE DU GnRH |
CA2552690C (en) | 2002-12-31 | 2014-12-09 | Ultra-Sonic Technologies, L.L.C. | Transdermal delivery using encapsulated agent activated by ultrasound and/or heat |
FR2849597B1 (fr) | 2003-01-08 | 2006-12-08 | Oreal | Composition cosmetique pour le soin des peaux grasses, contenant un acide gras carboxylique ou l'un de ses derives |
US7572780B2 (en) | 2003-01-21 | 2009-08-11 | Dimera, Incorporated | Method and kit for reducing the symptoms of peripheral vascular disease |
US20040146539A1 (en) | 2003-01-24 | 2004-07-29 | Gupta Shyam K. | Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits |
US20090318558A1 (en) | 2003-02-12 | 2009-12-24 | Jae-Hwan Kim | Solvent system of hardly soluble drug with improved dissolution rate |
US20040161435A1 (en) | 2003-02-14 | 2004-08-19 | Gupta Shyam K. | Skin Firming Anti-Aging Cosmetic Mask Compositions |
FR2851470B1 (fr) | 2003-02-20 | 2007-11-16 | Besins Int Belgique | Composition pharmaceutique pour administration transdermique ou transmuqueuse |
US20060194775A1 (en) | 2003-02-20 | 2006-08-31 | University Of Pittsburgh | Estradiol metabolites for the treatment of pulmonary hypertension |
JP4528296B2 (ja) | 2003-02-21 | 2010-08-18 | シェーリング アーゲー | Uv安定性経皮膏薬 |
FR2851918B1 (fr) | 2003-03-06 | 2006-06-16 | Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication | |
US7858607B2 (en) | 2003-03-14 | 2010-12-28 | Mamchur Stephen A | System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer |
US6956099B2 (en) | 2003-03-20 | 2005-10-18 | Arizona Chemical Company | Polyamide-polyether block copolymer |
ATE515493T1 (de) | 2003-03-31 | 2011-07-15 | Council Scient Ind Res | Mercaptophenylnaphthylmethan-derivate und deren herstellung |
US20040191207A1 (en) | 2003-03-31 | 2004-09-30 | Lipari John M. | Alpha-hydroxy acid ester drug delivery compositions and methods of use |
CN100434133C (zh) | 2003-04-29 | 2008-11-19 | 欧加农股份有限公司 | 反溶剂凝固方法 |
EP1620060B1 (en) | 2003-04-29 | 2010-03-24 | The General Hospital Corporation | Methods and devices for the sustained release of multiple drugs |
CA2524165A1 (en) | 2003-04-29 | 2004-11-11 | The Miriam Hospital | Selective testicular 11.beta.-hsd inhibitors and methods of use thereof |
US20040219124A1 (en) | 2003-05-01 | 2004-11-04 | Gupta Shyam K. | Cosmetic and Pharmaceutical Masks Based on Ion-Pair Delivery System |
JP4422430B2 (ja) | 2003-05-14 | 2010-02-24 | 帝國製薬株式会社 | エストロゲン及び/又はプロゲストゲン含有外用貼付剤 |
US7925519B2 (en) | 2003-05-20 | 2011-04-12 | Medencentive, Llc | Method and system for delivery of healthcare services |
ES2274456T3 (es) | 2003-05-22 | 2007-05-16 | Pantarhei Bioscience B.V. | Uso de composiciones que comprenden un componente estrogenico para el tratamiento y la prevencion del dolor musculoesqueletico. |
WO2005000266A2 (en) | 2003-05-22 | 2005-01-06 | Neopharm, Inc. | Liposomal formulations comprising a combination of two or more active agents |
TWI336627B (en) | 2003-05-23 | 2011-02-01 | Organon Nv | Drug delivery system,and use and manufacturing method thereof |
US7668735B2 (en) | 2003-05-30 | 2010-02-23 | Mdrxdirect Inc. | Compensated electronic consults |
US20040243437A1 (en) | 2003-05-30 | 2004-12-02 | Grace Joseph P. | Compensated electronic consults |
US20090227025A1 (en) | 2003-06-06 | 2009-09-10 | The Board Of Regents Of The University Of Texas System | Ex vivo human lung/immune system model using tissue engineering for studying microbial pathogens with lung tropism |
US20040253319A1 (en) | 2003-06-11 | 2004-12-16 | Shrirang Netke | Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy |
EA012783B1 (ru) | 2003-06-13 | 2009-12-30 | Джон Клод Савуар | Фармацевтическая композиция для контрацепции и заместительной гормональной терапии |
US20040259852A1 (en) | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
EP1488785A1 (de) | 2003-06-18 | 2004-12-22 | B. Braun Melsungen Ag | Ölemulsion zur postnatalen Hormonsubstitution |
US20110318405A1 (en) | 2003-06-25 | 2011-12-29 | Charles Erwin | Chemical Combination and Method for Increasing Delivery of Coenzyme Q10 |
CA2530397C (en) | 2003-06-27 | 2011-12-20 | Ovion, Inc. | Methods and devices for occluding body lumens and/or for delivering therapeutic agents |
US7074779B2 (en) | 2003-07-02 | 2006-07-11 | Ortho-Mcneil Pharmaceutical, Inc. | Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors |
EP1646634B1 (en) | 2003-07-08 | 2008-11-12 | Novartis AG | Use of rapamycin and rapamycin derivatives for the treatment of bone loss |
US7354876B2 (en) | 2003-07-09 | 2008-04-08 | Saint-Gobain Technical Fabrics Canada Ltd. | Fabric reinforcement and cementitious boards faced with same |
EP1648364A4 (en) | 2003-07-11 | 2010-05-26 | Macrochem Corp | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATION |
ES2237298B1 (es) | 2003-07-16 | 2006-11-01 | Italfarmaco, S.A. | Formulaciones mucoadhesivas semisolidas. |
WO2005009342A2 (en) | 2003-07-16 | 2005-02-03 | Pharmacia Corporation | Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith |
US20050042268A1 (en) | 2003-07-16 | 2005-02-24 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US20050025833A1 (en) | 2003-07-16 | 2005-02-03 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US20050020552A1 (en) | 2003-07-16 | 2005-01-27 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US20080069779A1 (en) | 2003-08-04 | 2008-03-20 | Foamix Ltd. | Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof |
CN101856348A (zh) | 2003-08-29 | 2010-10-13 | 斯隆-凯特林癌症研究所 | 联合治疗癌症的方法 |
SI1660009T1 (sl) | 2003-09-03 | 2015-07-31 | Miscon Trading S.A. | Metode za zdravljenje endometrioze |
DE602004018338D1 (de) | 2003-09-22 | 2009-01-22 | Onepharm Res And Dev Gmbh | Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund |
WO2005030175A1 (en) | 2003-09-29 | 2005-04-07 | Novo Nordisk Femcare Ag | Hrt formulations |
ES2933479T3 (es) | 2003-09-29 | 2023-02-09 | Novo Nordisk Healthcare Ag | Estabilidad mejorada de formulaciones de progestágenos |
JP2005104862A (ja) | 2003-09-29 | 2005-04-21 | Meiji Milk Prod Co Ltd | 加齢黄斑変性治療剤 |
US7247625B2 (en) | 2003-10-09 | 2007-07-24 | Wyeth | 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators |
HUP0303313A2 (hu) | 2003-10-09 | 2005-07-28 | Richter Gedeon Vegyészeti Gyár Rt. | Transzdermális gyógyszerkészítmények |
TW200517114A (en) | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
CA2542661A1 (en) | 2003-10-16 | 2005-05-06 | The Administrators Of The Tulane Educational Fund | Methods and compositions for treating cancer |
US8124118B2 (en) | 2003-10-22 | 2012-02-28 | Lidds Ab | Composition comprising biodegradable hydrating ceramics for controlled drug delivery |
EP2213295B1 (en) | 2003-10-24 | 2013-01-23 | Nora Therapeutics, Inc. | A method for obtaining data useful in the identification of a patient at risk of having difficulty in sustaining a pregnancy |
US20050101579A1 (en) | 2003-11-06 | 2005-05-12 | Shippen Eugene R. | Endometriosis treatment protocol |
DK1530965T3 (da) | 2003-11-11 | 2006-07-17 | Mattern Udo | Kontrolleret frigivelsesleveringssystem til nasal applikation |
DE602004017045D1 (de) | 2003-11-14 | 2008-11-20 | Warner Chilcott Co Inc | Graduierte östrogen-kontrazeptiva |
US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
EP1535618A1 (en) | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
US20050113350A1 (en) | 2003-11-26 | 2005-05-26 | Bernd Duesterberg | Extended use combination comprising estrogens and progestins |
US20050186183A1 (en) | 2003-12-08 | 2005-08-25 | Deangelo Joseph | Stabilized products, processes and devices for preparing same |
US20050129756A1 (en) | 2003-12-10 | 2005-06-16 | Hans-Peter Podhaisky | UV-stable, liquid or semisolid transdermal pharmaceutical preparation with light sensitive active ingredient |
CN1889994A (zh) | 2003-12-10 | 2007-01-03 | 艾克若克斯Dds有限公司 | 伴随透皮或局部药物输送的不希望的效果的治疗方法 |
MXPA06006810A (es) | 2003-12-17 | 2006-08-23 | Pfizer Prod Inc | Tratamiento de afecciones que se presentan con un nivel bajo de masa osea por terapia de combinacion continua con agonistas selectivos del receptor de prostaglandina ep4 y un estrogeno. |
WO2005065185A2 (en) | 2003-12-24 | 2005-07-21 | Collegium Pharmaceuticals, Inc. | Temperature-stable formulations, and methods of development thereof |
KR20070007277A (ko) | 2003-12-29 | 2007-01-15 | 우니베르시테트스클리니쿰 뮌스터 | Il-15에 의한 발모의 촉진 및 활성화를 위한 수단 |
IL159729A0 (en) | 2004-01-06 | 2004-06-20 | Doron I Friedman | Non-aqueous composition for oral delivery of insoluble bioactive agents |
AU2005204685B2 (en) | 2004-01-07 | 2007-06-21 | E-L Management Corporation | Cosmetic composition and method for retarding hair growth |
US20060084704A1 (en) | 2004-01-28 | 2006-04-20 | Charles Shih | Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof |
US20050182105A1 (en) | 2004-02-04 | 2005-08-18 | Nirschl Alexandra A. | Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function |
US7820702B2 (en) | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US20050271597A1 (en) | 2004-02-13 | 2005-12-08 | Keith Alec D | Prostate hypertrophy treatment composition and method |
DK1718258T3 (da) | 2004-02-23 | 2009-06-29 | Euro Celtique Sa | Misbrugssikker transdermal opioid-afgivelsesanordning |
US8052669B2 (en) | 2004-02-25 | 2011-11-08 | Femasys Inc. | Methods and devices for delivery of compositions to conduits |
US8147561B2 (en) | 2004-02-26 | 2012-04-03 | Endosphere, Inc. | Methods and devices to curb appetite and/or reduce food intake |
US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US7417040B2 (en) | 2004-03-01 | 2008-08-26 | Bristol-Myers Squibb Company | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US20050196434A1 (en) | 2004-03-04 | 2005-09-08 | Brierre Barbara T. | Pharmaceutical composition and method for the transdermal delivery of magnesium |
MY142989A (en) | 2004-03-10 | 2011-02-14 | Bayer Schering Pharma Ag | Stabilised supersaturated solids of lipophilic drugs |
WO2005087194A1 (en) | 2004-03-10 | 2005-09-22 | Schering Aktiengesellschaft | Compositions comprising drospirenone molecularly dispersed |
US20050220825A1 (en) | 2004-03-10 | 2005-10-06 | Adrian Funke | Molecular dispersions of drospirenone |
US20050222106A1 (en) | 2004-04-01 | 2005-10-06 | Stefan Bracht | Drospirenone-containing preparations for transdermal use |
EP1744714A4 (en) | 2004-04-07 | 2009-08-26 | Dermatrends Inc | TRANSDERMAL DISTRIBUTION SYSTEM FOR USE WITH BASIC PERMEATION IMPROVERS |
US20050228692A1 (en) | 2004-04-08 | 2005-10-13 | Hodgdon Darren W | Incentive based health care insurance program |
US20050228718A1 (en) | 2004-04-13 | 2005-10-13 | Pop Insights Inc. | Point of purchase research device |
US20050239747A1 (en) | 2004-04-21 | 2005-10-27 | Pharmaceutical Industry Technology And Development Center | Compositions and methods of enhanced transdermal delivery of steroid compounds and preparation methods |
US20050239758A1 (en) | 2004-04-21 | 2005-10-27 | Roby Russell R | Hormone treatment of multiple sclerosis |
RU2275930C2 (ru) | 2004-04-26 | 2006-05-10 | ООО "РусГен" | Композиция для коррекции возрастных изменений эндокринной системы человека (варианты) и способ получения фармацевтической формы на основе такой композиции |
US20050244522A1 (en) | 2004-04-30 | 2005-11-03 | Carrara Dario Norberto R | Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents |
EP1744750A2 (en) | 2004-05-06 | 2007-01-24 | Sandoz AG | Pharmaceutical composition comprising hydrophobic drug having improved solubility |
US20050250746A1 (en) | 2004-05-06 | 2005-11-10 | Matthew Iammatteo | Premenstrual dysphoric disorder medication |
PL1750766T3 (pl) | 2004-05-11 | 2013-12-31 | Eb Ip Lybrido B V | Preparaty farmaceutyczne i ich zastosowania do leczenia zaburzeń seksualnych u kobiet |
FR2870125B1 (fr) | 2004-05-12 | 2010-03-26 | Dermaconcept Jmc | Formulation du type spot-on utile en cosmetologie et en dermatologie |
US7899527B2 (en) | 2004-05-13 | 2011-03-01 | Palo Alto Investors | Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase |
US7534780B2 (en) | 2004-05-21 | 2009-05-19 | Bayer Schering Pharma Aktiengesellschaft | Estradiol prodrugs |
US7101342B1 (en) | 2004-05-24 | 2006-09-05 | Caillouette James C | Detection of menopause status and treatment thereof |
WO2005117898A1 (en) | 2004-05-26 | 2005-12-15 | Wyeth | Compositions and methods for treatment of premenstrual dysphoric disorder |
WO2005120517A1 (en) | 2004-06-07 | 2005-12-22 | Strides Arcolab Limited | Stable liquid suspension formulation comprising synthetic steroids and process for producing the same |
US20070196453A1 (en) | 2004-06-07 | 2007-08-23 | Jie Zhang | Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs |
DE102004028284A1 (de) | 2004-06-11 | 2006-01-05 | Hexal Ag | Matrixkontrolliertes transdermales therapeutisches System auf Basis eines Schmelzklebstoffs zur Anwendung von Norelgestromin |
US7485666B2 (en) | 2004-06-17 | 2009-02-03 | Kimberly-Clark Worldwide, Inc. | Vaginal health products |
US7235563B2 (en) | 2004-06-21 | 2007-06-26 | Bristol-Myers Squibb Company | Spirocyclic compounds useful as modulators of nuclear hormone receptor function |
TW200603813A (en) | 2004-07-07 | 2006-02-01 | Wyeth Corp | Cyclic progestin regimens and kits |
FR2873585B1 (fr) | 2004-07-27 | 2006-11-17 | Aventis Pharma Sa | Nouvelles formulations galeniques de principes actifs |
EP1778187B1 (en) | 2004-08-04 | 2012-05-23 | Camurus Ab | Compositions forming non-lamellar dispersions |
GT200500183A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
GT200500185A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
US20060034889A1 (en) | 2004-08-16 | 2006-02-16 | Macromed, Inc. | Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof |
US20060040904A1 (en) | 2004-08-17 | 2006-02-23 | Ahmed Salah U | Vaginal cream compositions, kits thereof and methods of using thereof |
TW200616604A (en) | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
US7879830B2 (en) | 2004-09-02 | 2011-02-01 | Wiley Teresa S | Hormone replacement composition and method |
US20070167418A1 (en) | 2004-09-07 | 2007-07-19 | Ferguson Steven W | Progesterone/testosterone cream for erectile dysfunction |
US9028852B2 (en) | 2004-09-07 | 2015-05-12 | 3M Innovative Properties Company | Cationic antiseptic compositions and methods of use |
EP2301557A1 (en) | 2004-09-09 | 2011-03-30 | Warburton Technology Limited | Trace elements |
AR043476A1 (es) | 2004-09-09 | 2005-08-03 | Dvoskin Victor Oscar | Dispositivo de administracion regulada de sustancias para la insercion en una cavidad corporal y procedimiento para fabricar un medio de soporte de dichas sustancias |
JP2008513375A (ja) | 2004-09-13 | 2008-05-01 | ピーアール ファーマシューティカルズ,インコーポレイテッド | エストラジオール代謝産物の長期間作用型の注射可能な結晶性処方物およびその使用法 |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
US20060058238A1 (en) | 2004-09-15 | 2006-03-16 | Lee Laurent-Applegate | Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same |
US20070254314A1 (en) | 2004-09-16 | 2007-11-01 | Geier Mark R | Methods of treating autism and autism spectrum disorders |
ES2366193T3 (es) | 2004-09-20 | 2011-10-18 | Janssen Pharmaceutica Nv | Nuevos derivados que contienen heteroátomos tetracíclicos útiles como moduladores de receptores de hormonas esteroideas sexuales. |
US20060062758A1 (en) | 2004-09-21 | 2006-03-23 | Nastech Pharmaceutical Comapny Inc. | Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds |
US20060121102A1 (en) | 2004-09-27 | 2006-06-08 | Chia-Ming Chiang | Transdermal systems for the delivery of estrogens and progestins |
EP1796725B1 (en) | 2004-09-27 | 2008-07-23 | Pantarhei Bioscience B.V. | Treatment or prevention of unscheluded bleeding in women on progestogen containing medication |
US20070111975A1 (en) | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
AP2365A (en) | 2004-10-20 | 2012-02-20 | Endorech Inc | Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 CGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women. |
US7569725B2 (en) | 2004-10-21 | 2009-08-04 | Britsol-Myers Squibb Company | Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US8022053B2 (en) | 2004-11-02 | 2011-09-20 | Bayer Schering Pharma Aktiengesellschaft | Oral solid dosage forms containing a low dose of estradiol |
EP1806152B1 (en) | 2004-11-10 | 2012-08-01 | Hisamitsu Pharmaceutical Co., Inc. | Drug for external use and adhesive patch |
US20060106004A1 (en) | 2004-11-12 | 2006-05-18 | Brody Steven A | Unique methods and formulations of bio-identical sex steroids for the treatment of pathophysiologic aberrations of menopause |
US20060110415A1 (en) | 2004-11-22 | 2006-05-25 | Bioderm Research | Topical Delivery System for Cosmetic and Pharmaceutical Agents |
US8121886B2 (en) | 2004-12-03 | 2012-02-21 | Ryma Technology Solutions Inc. | Confidence based selection for survey sampling |
US7465587B2 (en) | 2004-12-03 | 2008-12-16 | Genzyme Corporation | Diagnostic assay device |
AT501408B1 (de) | 2004-12-07 | 2011-03-15 | Physikalisches Buero Steinmueller Gmbh | Biologische oberflächen |
JP2008524222A (ja) | 2004-12-17 | 2008-07-10 | バイオノボ・インコーポレーテッド | Morusalbaのエストロゲン様抽出物およびその使用 |
US20060134188A1 (en) | 2004-12-20 | 2006-06-22 | Hans-Peter Podhaisky | Transdermal pharmaceutical preparation with a progesterone A-specific ligand (PRASL) as active ingredient |
US20070060589A1 (en) | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
US20070036843A1 (en) | 2005-01-28 | 2007-02-15 | Collegium Pharmaceutical, Inc. | Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents |
ITMI20050262A1 (it) | 2005-02-21 | 2006-08-22 | Carlo Ghisalberti | Sostanze composizioni e metodi di trattamento dell'alopecia |
US8703198B2 (en) | 2005-03-02 | 2014-04-22 | Aquatrove Biosciences | Water-based personal moisturizers and lubricants, in particular vaginal lubricants, and uses thereof |
US7473687B2 (en) | 2005-03-24 | 2009-01-06 | Emory University | Methods for the treatment of a traumatic central nervous system injury |
US7405186B2 (en) | 2005-03-25 | 2008-07-29 | Chemsil Silicones, Inc. | Lubricant compositions, condom products and methods of making same |
CA2603649C (en) | 2005-04-08 | 2014-10-14 | Ozpharma Pty Ltd | Buccal delivery system |
CA2604431A1 (en) | 2005-04-13 | 2006-10-26 | Unimed Pharmaceuticals, Inc. | Method of increasing testosterone and related steroid concentrations in women |
US20060235037A1 (en) | 2005-04-15 | 2006-10-19 | Purandare Ashok V | Heterocyclic inhibitors of protein arginine methyl transferases |
WO2006113505A2 (en) | 2005-04-15 | 2006-10-26 | Clarus Therapeutics, Inc. | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
WO2007124250A2 (en) | 2006-04-21 | 2007-11-01 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
US9205047B2 (en) | 2005-04-25 | 2015-12-08 | The Governing Council Of The University Of Toronto | Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix |
US7767656B2 (en) | 2005-04-25 | 2010-08-03 | Molly S Shoichet | Blends of temperature sensitive and anionic polymers for drug delivery |
US8962013B2 (en) | 2005-05-02 | 2015-02-24 | Bayer Intellectual Property Gmbh | Multi-layered transdermal system with triazine UV absorber |
US20060252049A1 (en) | 2005-05-04 | 2006-11-09 | Shuler Richard O | Growth-promoting and immunizing subcutaneous implant |
US7862552B2 (en) | 2005-05-09 | 2011-01-04 | Boston Scientific Scimed, Inc. | Medical devices for treating urological and uterine conditions |
US20060251581A1 (en) | 2005-05-09 | 2006-11-09 | Mcintyre Jon T | Method for treatment of uterine fibroid tumors |
US8048017B2 (en) | 2005-05-18 | 2011-11-01 | Bai Xu | High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances |
AU2006249349B2 (en) | 2005-05-26 | 2012-01-12 | Teva Women's Health, Inc. | Oral dosage forms comprising progesterone and methods of making and using the same |
ES2607454T3 (es) | 2005-06-03 | 2017-03-31 | Acrux Dds Pty Ltd | Método y composición para el suministro transdérmico de testosterona |
ITBO20050388A1 (it) | 2005-06-06 | 2006-12-07 | Alfa Wassermann Spa | Formulazione mucoadesive utili in dispositivi medici in preparazioni farmaceutiche |
US20060280795A1 (en) | 2005-06-08 | 2006-12-14 | Dexcel Pharma Technologies, Ltd. | Specific time-delayed burst profile delivery system |
CN103989687A (zh) | 2005-06-09 | 2014-08-20 | 惠氏公司 | 含有炔雌醇的tanaproget组合物 |
US20060292223A1 (en) | 2005-06-16 | 2006-12-28 | Warner Chilcott Company Inc, | Gel compositions for topical administration |
CA2612380C (en) | 2005-06-16 | 2017-06-06 | Warner Chilcott Company, Inc. | Estrogen compositions for vaginal administration |
CA2612415A1 (en) | 2005-06-16 | 2006-12-28 | Warner Chilcott Company, Inc. | Estrogen compositions for vaginal administration |
TW200726473A (en) | 2005-06-28 | 2007-07-16 | Wyeth Corp | Compositions and methods for treatment of cycle-related symptoms |
SG166107A1 (en) | 2005-06-29 | 2010-11-29 | Warner Chilcott Co Llc | Quadraphasic continuous graduated estrogen contraceptive |
US20070010550A1 (en) | 2005-07-08 | 2007-01-11 | The Board Of Regents Of The University Of Texas | Scopolamine to Reduce or Eliminate Hot Flashes, Night Sweats, and Insomnia |
US20070014839A1 (en) | 2005-07-18 | 2007-01-18 | Stefan Bracht | Decomposer film for transdermal patches |
DE102005034498A1 (de) | 2005-07-20 | 2007-01-25 | Grünenthal GmbH | Orale Kontrazeption mit Trimegeston |
US8195403B2 (en) | 2005-07-21 | 2012-06-05 | The Invention Science Fund I, Llc | Selective resonance of bodily agents |
US20070027107A1 (en) | 2005-07-29 | 2007-02-01 | Curt Hendrix | Compositions and methods for treating estrogen-dependent diseases and conditions |
PE20070341A1 (es) | 2005-07-29 | 2007-04-13 | Wyeth Corp | Derivados de pirrol como moduladores del receptor de progesterona |
US10137135B2 (en) | 2005-08-15 | 2018-11-27 | Allergan Sales, Llc | Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith |
CN101291663A (zh) | 2005-09-16 | 2008-10-22 | 赛诺科学股份公司 | 预防和治疗睡眠呼吸障碍的方法和工具 |
US7319152B2 (en) | 2005-09-19 | 2008-01-15 | Wyeth | 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators |
US20070066628A1 (en) | 2005-09-19 | 2007-03-22 | Wyeth | 5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators |
US7414142B2 (en) | 2005-09-19 | 2008-08-19 | Wyeth | 5-aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators |
EP1928488A4 (en) | 2005-09-27 | 2009-07-22 | Stem Cell Therapeutics Corp | REGULATION OF OLIGODENDROCYTE PRECURSOR CELL PROLIFERATION WITH PROLACTIN |
EP1945193A1 (en) | 2005-10-06 | 2008-07-23 | Pantec Biosolutions AG | Transdermal delivery system for treating infertility |
US7550458B2 (en) | 2005-10-18 | 2009-06-23 | Bristol-Myers Squibb Company | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function |
EP1954303A2 (en) | 2005-10-19 | 2008-08-13 | Scott Josephson | Improved reproductive management |
CA2626337C (en) | 2005-10-19 | 2015-12-29 | Chavah Pty Ltd | Reduction of side effects from aromatase inhibitors used for treating breast cancer |
US8096940B2 (en) | 2005-10-19 | 2012-01-17 | Iversync Ii Llc | Reproductive management |
DE102005050729A1 (de) | 2005-10-19 | 2007-04-26 | Schering Ag | Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption |
SG180041A1 (en) | 2005-10-24 | 2012-05-30 | Manawatu Biotech Invest Ltd | Ovulation cycle monitoring and management |
US20070093548A1 (en) | 2005-10-25 | 2007-04-26 | Wyeth | Use of progesterone receptor modulators |
IE20050723A1 (en) | 2005-10-28 | 2007-05-30 | Patrick T Prendergast | Anti-mineralocorticoid therapy of infection |
US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
EP1951250A4 (en) | 2005-11-22 | 2009-12-16 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
US20080306036A1 (en) | 2005-11-22 | 2008-12-11 | Subba Reddy Katamreddy | Triphenylethylene Compounds Useful as Selective Estrogen Modulators |
JP2009516746A (ja) | 2005-11-22 | 2009-04-23 | スミスクライン ビーチャム コーポレーション | 化合物 |
CN101484000A (zh) | 2005-11-22 | 2009-07-15 | 史密丝克莱恩比彻姆公司 | 化合物 |
US20080255078A1 (en) | 2005-11-22 | 2008-10-16 | Subba Reddy Katamreddy | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators |
US20070116829A1 (en) | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | Pharmaceutical Composition with High-Potency Sweetener |
TWI389709B (zh) | 2005-12-01 | 2013-03-21 | Novartis Ag | 經皮治療系統 |
GB0524961D0 (en) | 2005-12-07 | 2006-01-18 | Pharmakodex Ltd | Transdermal administration of active agents for systemic effect |
US8337814B2 (en) | 2005-12-15 | 2012-12-25 | Topical Sinus Therapeutics, Inc. | Treatment of active infections, sinusitis, rhinitis, and related neurological disorders and related compositions |
CA2631493A1 (en) | 2005-12-15 | 2007-06-21 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration |
WO2007092085A2 (en) | 2005-12-20 | 2007-08-16 | Howard Murad | Fragranced therapeutic delivery system |
EP1970040A4 (en) | 2005-12-22 | 2013-05-29 | Otsuka Pharma Co Ltd | METHOD FOR PRODUCING MEDICINAL WAX MATRIX PARTICLES, IN THE METHOD OF USING EXTRUDERS AND CILOSTAZOL-CONTAINING PREPARATION WITH DELAYED RELEASE |
US9393218B2 (en) | 2005-12-23 | 2016-07-19 | Epinamics Gmbh | Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers |
US8318898B2 (en) | 2005-12-23 | 2012-11-27 | Universite De Lausanne | Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation |
US8217024B2 (en) | 2005-12-27 | 2012-07-10 | Teva Women's Health, Inc. | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof |
BRPI0620745A2 (pt) | 2005-12-28 | 2013-02-19 | Dabur Pharma Ltd | polÍmero biocompatÍvel, nço-biodegradÁvel, nço tàxico, de ultilidade para composiÇÕes de nanopartÍculas farmacÊuticas |
KR100750320B1 (ko) | 2006-01-04 | 2007-08-17 | 학교법인 포항공과대학교 | 쿠커비투릴을 포함하는 젤 |
DK1973529T3 (da) | 2006-01-05 | 2011-09-12 | Veloxis Pharmaceuticals As | Fyldbar tablet, som er i stand til at falde hen |
KR100784485B1 (ko) | 2006-01-18 | 2007-12-11 | 한국과학기술연구원 | 생분해성 온도 감응성 폴리포스파젠계 하이드로젤, 그의제조방법 및 그의 용도 |
JP2009523831A (ja) | 2006-01-20 | 2009-06-25 | ペア トゥリー ファーマシューティカルズ インコーポレイテッド | 萎縮性膣炎を治療する方法 |
EP1973952A4 (en) | 2006-01-23 | 2010-09-01 | Kwangju Inst Sci & Tech | CONJUGATE COMPRISING A COVALENT TO A MUCOADHESIVE POLYMER-ASSOCIATED PHARMACEUTICALLY ACTIVE COMPOUND, AND A TRANSMUCOSAL ADMINISTRATION METHOD FOR A PHARMACEUTICALLY ACTIVE COMPOUND USING THEREOF |
WO2007117352A2 (en) | 2006-02-08 | 2007-10-18 | Howard Murad | Topical therapeutic delivery system |
EP1991218A4 (en) | 2006-02-24 | 2010-11-03 | Axelar Ab | USE OF CYCLOLIGNANS IN THE TREATMENT OF TYPE 2 DIABETES AND AS CONTRACEPTIVES |
SG172654A1 (en) | 2006-03-02 | 2011-07-28 | Warner Chilcott Co Llc | Extended cycle multiphasic oral contraceptive method |
US20070207225A1 (en) | 2006-03-03 | 2007-09-06 | Francesco Squadrito | Genistein modulated reduction of cardiovascular risk factors |
GB0604535D0 (en) | 2006-03-07 | 2006-04-12 | Sndv Sprl | Betulonic acid derivatives |
US20070264349A1 (en) | 2006-03-07 | 2007-11-15 | Novavax, Inc. | Nano-structured compositions and methods of making and using the same |
KR100746962B1 (ko) | 2006-04-04 | 2007-08-07 | 한국과학기술연구원 | 온도 감응성 포스파젠계 고분자-생리 활성 물질 복합체,그의 제조방법 및 그의 용도 |
EP2004200A2 (en) | 2006-04-05 | 2008-12-24 | Wyeth a Corporation of the State of Delaware | Methods for prevention and treatment of conditions arising from local estrogen deficiency |
WO2007118205A2 (en) | 2006-04-07 | 2007-10-18 | University Of Maryland, Baltimore | Compounds, compositions and methods for treating hormone-dependent maladies |
CA2648360A1 (en) | 2006-04-07 | 2007-11-01 | Novavax, Inc. | Nanostructured compositions having antibacterial, anti-fungal, anti-yeast, and/or anti-viral properties |
WO2007120868A2 (en) | 2006-04-14 | 2007-10-25 | Stanley Kepka | Bioavailability enhancement of lipophilic drug by use solvent system |
US8399012B2 (en) | 2006-04-17 | 2013-03-19 | Kimberly-Clark Worldwide, Inc. | Degradable therapeutic delivery device |
FR2900052B1 (fr) | 2006-04-19 | 2011-02-18 | Galderma Sa | Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine |
US20080039405A1 (en) | 2006-04-25 | 2008-02-14 | Croda, Inc. | Modification of percutaneous absorption of topically active materials |
US20070254858A1 (en) | 2006-04-27 | 2007-11-01 | Cronk Peter J | Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects |
EP2023898A1 (en) | 2006-05-10 | 2009-02-18 | Evonik Degussa GmbH | Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions |
AU2007256718A1 (en) | 2006-06-02 | 2007-12-13 | Pear Tree Women's Health Care | Method of treating atrophic vaginitis |
US20070281008A1 (en) | 2006-06-05 | 2007-12-06 | Lin Shun Y | Personal lubricant compositions and kits for providing personal lubrication |
US20070287789A1 (en) | 2006-06-07 | 2007-12-13 | Stephen Ray Jones | Bleed-resistant colored microparticles |
US20070286819A1 (en) | 2006-06-08 | 2007-12-13 | Warner Chilcott Company, Inc. | Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability |
US20080113953A1 (en) | 2006-06-08 | 2008-05-15 | Warner Chilcott Company, Inc. | Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability |
US20080021003A1 (en) | 2006-06-13 | 2008-01-24 | Vladimir Hanes | Extended step-down estrogen regimen |
US20070292493A1 (en) | 2006-06-15 | 2007-12-20 | Brierre Barbara T | Pharmaceutical composition and method for the transdermal delivery of calcium |
US8288366B2 (en) | 2006-06-20 | 2012-10-16 | Chochinov Ronald H | Formulation for hair growth |
EP1872775A1 (en) | 2006-06-29 | 2008-01-02 | Polichem S.A. | Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders |
WO2008006093A2 (en) | 2006-07-06 | 2008-01-10 | University Of Medicine And Dentistry Of New Jersey | Estrogen receptor modulators and uses thereof |
US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
EP1880715A1 (en) | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
JP5270542B2 (ja) | 2006-07-22 | 2013-08-21 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
DE102006035549A1 (de) | 2006-07-27 | 2008-01-31 | Evonik Röhm Gmbh | Arzneiform mit mindestens zweischichtiger Trennschicht |
US20080026062A1 (en) | 2006-07-31 | 2008-01-31 | Isaac Farr | Pharmaceutical compositions including nano-sized active agent |
US20080026040A1 (en) | 2006-07-31 | 2008-01-31 | Isaac Farr | Active agent-releasing dosage forms |
US20080038219A1 (en) | 2006-08-07 | 2008-02-14 | Calgenex Corporation | Novel Composition for a Topical Skin Treatment Base and Medicated Applications Thereof |
US20080038350A1 (en) | 2006-08-10 | 2008-02-14 | Hagen Gerecke | Low-dosage peroral medication for contraception containing crystalline dienogest and ethinyl estradiol |
US20080085877A1 (en) | 2006-08-10 | 2008-04-10 | Drugtech Corporation | Therapeutic methods of using estrogen compositions |
US20080095831A1 (en) | 2006-08-10 | 2008-04-24 | Mc Graw Thomas L | Topical formulation of multilamellar vesicles composition for percutaneous absorption of pharmaceutically active agent |
US7853607B2 (en) | 2006-08-25 | 2010-12-14 | Sap Ag | Related actions server |
BRPI0714754A2 (pt) | 2006-09-08 | 2013-05-14 | Foamix Ltd | composiÇço tàpica colorida ou colorÍvel, mÉtodo para a mudanÇa de cor de uma composiÇço tàpica colorida ou colorÍvel e kit para aplicaÇço tàpica |
WO2008033024A2 (en) | 2006-09-15 | 2008-03-20 | Echo Pharmaceuticals B.V. | Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances |
CA2662956A1 (en) | 2006-09-16 | 2008-03-20 | Bayer Schering Pharma Aktiengesellschaft | Oral modified release formulations |
CA2664427C (en) | 2006-10-04 | 2012-06-05 | M & P Patent Aktiengesellschaft | Controlled release delivery system for nasal application of neurotransmitters |
EP2174938A1 (en) | 2006-10-12 | 2010-04-14 | SuperGen, Inc. | Quinoline derivatives for modulating DNA methylation |
WO2008062466A2 (en) | 2006-10-13 | 2008-05-29 | Reliance Life Sciences Pvt. Ltd. | Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer |
EP1930010A1 (de) | 2006-10-20 | 2008-06-11 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido |
EP1915986A1 (en) | 2006-10-23 | 2008-04-30 | BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH | Lipid growth factor formulations |
WO2008084286A2 (en) | 2006-10-25 | 2008-07-17 | Arterial Remodeling Technologies, S.A. | Method for expansion and deployment of polymeric structures including stents |
DE102006050558B4 (de) | 2006-10-26 | 2009-03-26 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution |
US20090214474A1 (en) | 2006-11-01 | 2009-08-27 | Barbara Brooke Jennings | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
US20080103116A1 (en) | 2006-11-01 | 2008-05-01 | Jennings-Spring Barbara L | Method of treatment and compositions of D-chiro inositol and phosphates thereof |
EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
WO2008063910A2 (en) | 2006-11-08 | 2008-05-29 | Novavax, Inc. | Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US7829116B2 (en) | 2006-11-14 | 2010-11-09 | Momentive Performance Materials Inc. | Adhesive-forming composition and blend of adhesives obtained therefrom |
DE102006054731B4 (de) | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie |
RU2009117201A (ru) | 2006-11-29 | 2011-01-10 | Вайет (Us) | Двухслойные таблетки на основе эстрогена/селективного модулятора эстрогенового рецептора и эстрогена/прогестина |
WO2008152444A2 (en) | 2006-11-29 | 2008-12-18 | Foamix Ltd. | Foamable waterless compositions with modulating agents |
US20080132475A1 (en) | 2006-12-05 | 2008-06-05 | Charles Gerald Connor | Treatment for dry eye |
US9918934B2 (en) | 2006-12-12 | 2018-03-20 | Edgar Joel Acosta-Zara | Linker-based lecithin microemulsion delivery vehicles |
US20080145423A1 (en) | 2006-12-14 | 2008-06-19 | Ajmal Ali Khan | Chewable tablet and method of formulating |
WO2008079898A1 (en) | 2006-12-20 | 2008-07-03 | Pharmwest, Inc. | Methods and topical formulations comprising colloidal metal for treating or preventing skin conditions |
DK2111401T3 (da) | 2006-12-20 | 2011-05-30 | Bayer Healthcare Llc | 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}carbamoyl)-amino]-3-fluorphenoxy}-N-methylpyridin-2-carboxamid samt prodrug og salte heraf til behandling af cancer |
US20080153789A1 (en) | 2006-12-26 | 2008-06-26 | Femmepharma Holding Company, Inc. | Topical administration of danazol |
TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明(cyclopamine)類似物類 |
GB2445539A (en) | 2006-12-29 | 2008-07-16 | Ardana Bioscience Ltd | Bigel composition |
US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
EP2106272A4 (en) | 2007-01-11 | 2011-05-04 | Acrux Dds Pty Ltd | SPREIZUTENSIL |
EP2117518A2 (en) | 2007-01-12 | 2009-11-18 | Wyeth a Corporation of the State of Delaware | Tablet-in-tablet compositions |
RU2009131749A (ru) | 2007-01-22 | 2011-02-27 | Новавакс, Инк. (Us) | Многофазные фармацевтические композиции плохо растворимых в воде лекарственных соединений для уменьшения вариабельности при приеме после еды/натощак и для улучшения пероральной биодоступности |
US8828981B2 (en) | 2007-02-06 | 2014-09-09 | George Creasy | Progesterone for the treatment or prevention of spontaneous preterm birth |
IL181217A0 (en) | 2007-02-08 | 2007-07-04 | Haim Levy | Pharmaceuticalcompositions based on a microemulsion |
WO2008121447A1 (en) | 2007-02-14 | 2008-10-09 | Northwestern University | Self-assembling membranes and related methods thereof |
JP2011512164A (ja) | 2007-02-20 | 2011-04-21 | ガルデルマ・リサーチ・アンド・デヴェロップメント | 皮膚内への治療物質の送達方法 |
US20080206156A1 (en) | 2007-02-22 | 2008-08-28 | Cronk Peter J | Continuous spray scalp therapy and dispensing systems for same |
WO2008106149A1 (en) | 2007-02-28 | 2008-09-04 | Children's Medical Center Corporation | Methods for predicting the onset of menarche |
US20080214512A1 (en) | 2007-03-01 | 2008-09-04 | Christian Seitz | Pharmaceutical preparation containing a gestagen, and kit and method for treating endometriosis using the preparation |
DE102007011486A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Arzneimittel umfassend wenigstens ein Gestagen |
US20080226698A1 (en) | 2007-03-16 | 2008-09-18 | Mylan Technologies, Inc. | Amorphous drug transdermal systems, manufacturing methods, and stabilization |
MX337408B (es) | 2007-03-22 | 2016-03-03 | Berg Llc | Formulaciones topicas que tienen biodisponibilidad aumentada. |
US20090017120A1 (en) | 2007-03-23 | 2009-01-15 | Humco Holding Group, Inc. | Phase stable lecithin organogel composition |
EP2148681B1 (en) | 2007-04-20 | 2016-03-16 | PregLem S.A. | Selective progesterone modulators in the treatment of uterine bleeding |
EP1988098A1 (en) | 2007-04-27 | 2008-11-05 | AEterna Zentaris GmbH | Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors |
WO2008140794A1 (en) | 2007-05-11 | 2008-11-20 | The Texas A & M University System | Hormone normalization therapy and uses thereof |
US20080312198A1 (en) | 2007-06-14 | 2008-12-18 | Rodriguez Gustavo C | Pharmaceutical products containing hormones and a 25-hydroxy vitamin d compound |
US20080312197A1 (en) | 2007-06-14 | 2008-12-18 | Rodriguez Gustavo C | Pharmaceutical products containing hormones and a 25-hydroxy vitamin d compound |
KR100968591B1 (ko) | 2007-06-14 | 2010-07-08 | 한국과학기술연구원 | 약물전달용 폴리포스파젠계 하이드로젤, 그의 제조방법 및그의 용도 |
CA2691654C (en) | 2007-06-21 | 2016-06-07 | Pantarhei Bioscience B.V. | Treatment of meconium aspiration syndrome with estrogens |
ES2310968B1 (es) | 2007-06-25 | 2010-02-08 | Italfarmaco, S.A. | Uso de estriol en bajas dosis. |
WO2009003125A1 (en) | 2007-06-26 | 2008-12-31 | Warner Chilcott Company,Inc. | Intravaginal drug delivery devices for the delivery of macromolecules and water-soluble drugs |
US8992977B2 (en) | 2007-06-27 | 2015-03-31 | Samos Pharmaceuticals, Llc | Multi-day delivery of biologically active substances |
FR2918277B1 (fr) | 2007-07-06 | 2012-10-05 | Coretecholding | Nouveau procede de production de formes pharmaceutiques seches hydrodispersibles et les compositions hydrodispersibles ainsi obtenues |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
KR100937625B1 (ko) | 2007-08-10 | 2010-01-20 | 주식회사 제닉 | 가용성 웹 공극필름 및 이의 제조방법 |
US8268806B2 (en) | 2007-08-10 | 2012-09-18 | Endorecherche, Inc. | Pharmaceutical compositions |
US20090060997A1 (en) | 2007-08-27 | 2009-03-05 | Christian Seitz | Process for producing a pharmaceutical preparation for therapeutic treatment of endometriosis containing a combination of a gestagen and (6s)-5-methyltetrahydrofolate |
WO2009056991A2 (en) | 2007-09-04 | 2009-05-07 | Foamix Ltd. | Device for delivery of a foamable composition |
EP2205236A4 (en) | 2007-09-06 | 2012-08-22 | Regain Biotechnology Pvt Ltd | NEW MEANS FOR THE TREATMENT OF DISEASES AND FUNCTIONAL DISORDERS |
AR068409A1 (es) | 2007-09-14 | 2009-11-18 | Drugtech Corp | Composiciones farmaceuticas, transdermicas sin alcohol |
KR101083696B1 (ko) | 2007-09-20 | 2011-11-15 | 가부시키가이샤 시세이도 | 경피 흡수 제제 |
US8741329B2 (en) | 2007-09-21 | 2014-06-03 | Merck Sharp & Dohme B.V. | Drug delivery system |
HUE043897T2 (hu) | 2007-09-25 | 2019-09-30 | Solubest Ltd | Lipofil hatóanyagot tartalmazó készítmények és eljárás elõállításukra |
EP2195033A1 (en) | 2007-10-08 | 2010-06-16 | Fovea Pharmaceuticals SA | Aqueous ophthalmic formulations |
US20090099149A1 (en) | 2007-10-11 | 2009-04-16 | Wyeth | Bioadhesive film |
US7939546B2 (en) | 2007-10-12 | 2011-05-10 | Supergen, Inc. | Quinoline derivatives for modulating DNA methylation |
US7790746B2 (en) | 2007-10-12 | 2010-09-07 | Supergen, Inc. | Quinoline derivatives for modulating DNA methylation |
US8507465B2 (en) | 2007-10-25 | 2013-08-13 | Lupin Limited | Antiemetic-oral contraceptive combination |
NZ585033A (en) | 2007-11-02 | 2011-12-22 | Acrux Dds Pty Ltd | Transdermal delivery system |
US20090130029A1 (en) | 2007-11-21 | 2009-05-21 | Foamix Ltd. | Glycerol ethers vehicle and pharmaceutical compositions thereof |
WO2009070794A1 (en) | 2007-11-29 | 2009-06-04 | Jackson Gregg A | Progesterone-containing compositions and devices |
US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
US8420624B2 (en) | 2007-12-04 | 2013-04-16 | Yung Shin Pharm. Ind. Co., Ltd. | Methods for treating or preventing symptoms of hormonal variations |
WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
FR2924942B1 (fr) | 2007-12-14 | 2012-06-15 | Pf Medicament | Compositions pharmaceutiques transcutanees contenant une hormone steroidienne |
US8762865B2 (en) | 2007-12-19 | 2014-06-24 | The Iams Company | Interactive survey feedback tool |
CA2712120A1 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
US20090181068A1 (en) | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
GB0801876D0 (en) | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
GB0802403D0 (en) | 2008-02-08 | 2008-03-12 | Probiox Sa | Compositions for the treatment of oxidative stress |
WO2009111574A2 (en) | 2008-03-05 | 2009-09-11 | Evestra, Inc. | BISMETHYLENE-17α CARBOLACTONES AND RELATED USES |
US20090232897A1 (en) | 2008-03-14 | 2009-09-17 | Bijayananda Sahoo | Pharmaceutical compositions comprising conjugated estrogens |
CA2721072A1 (en) | 2008-04-11 | 2009-10-15 | Bionovo, Inc. | Anticancer methods employing extracts of gleditsia sinensis lam |
CN102056611A (zh) | 2008-04-14 | 2011-05-11 | Posi维森纳里解决方案有限责任公司 | 用于获得不同的治疗适应症所需要的血浆孕酮水平的方法和药物组合物 |
ES2327201B1 (es) | 2008-04-23 | 2010-07-23 | Ignacio Umbert Millet | Composicion farmaceutica personalizada para el rejuvenecimiento de la piel que contiene acido retinoico. |
US20090269403A1 (en) | 2008-04-24 | 2009-10-29 | Shaked Ze Ev | Oral contraceptive dosage forms and methods of making such dosage forms |
TWI477276B (zh) | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
GB0807605D0 (en) | 2008-04-28 | 2008-06-04 | Diurnal Ltd | Lipid composition |
US20090285869A1 (en) | 2008-05-14 | 2009-11-19 | Humco Holding Group, Inc. | Salt stable lecithin organogel composition |
WO2009142743A1 (en) | 2008-05-20 | 2009-11-26 | Cantimer, Inc. | Methods, systems and devices for analyzing a surfactant-treated biological fluid sample |
JP2011523704A (ja) | 2008-05-20 | 2011-08-18 | カンタイマー,インコーポレイティド | イオン交換によって生体液試料を分析するための方法、システム、及び装置 |
WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
HUE035770T2 (en) | 2008-06-16 | 2018-05-28 | Pfizer | Process for the preparation of diblock copolymers functionalized with targeting material for use in the preparation of therapeutic nanoparticles |
WO2009158584A1 (en) | 2008-06-27 | 2009-12-30 | Wyeth | Dual adhesive technology |
EP2140860A1 (en) | 2008-07-03 | 2010-01-06 | Bayer Schering Pharma Oy | An improved method of contraception |
US20110190201A1 (en) | 2008-07-24 | 2011-08-04 | Searete Llc | Method, device, and kit for maintaining physiological levels of steroid hormone in a subject |
US20100028360A1 (en) | 2008-07-26 | 2010-02-04 | Craig Stephen Atwood | Methods for the modulation of brain progestagen signaling in the prevention and treatment of neurological disorders and neurodegenerative diseases |
IT1392903B1 (it) | 2008-07-29 | 2012-04-02 | Marino Salin | Composizione comprendente un'associazione di principi attivi per uso nel trattamento topico della calvizie |
TW201008569A (en) | 2008-08-08 | 2010-03-01 | Bayer Schering Pharma Ag | Progestin-containing drug delivery system |
US20100040671A1 (en) | 2008-08-12 | 2010-02-18 | Ahmed Salah U | Intravaginal Devices With a Rigid Support, Methods of Making, and Uses Thereof |
CN102177253A (zh) | 2008-08-28 | 2011-09-07 | 德玛泰克国际公司 | 测定皮肤样品的年龄范围 |
EP2340041A2 (en) | 2008-09-08 | 2011-07-06 | Hoffman/Barrett, L.L.C. | Porphyrazine optical and dual optical/mr contrast and therapeutic agents |
WO2010030763A2 (en) | 2008-09-10 | 2010-03-18 | Bind Biosciences, Inc. | High throughput fabrication of nanoparticles |
AU2009290656B2 (en) | 2008-09-12 | 2015-05-07 | Critical Pharmaceuticals Limited | Improvements in the absorption of therapeutic agents across mucosal membranes or the skin |
WO2010033188A2 (en) | 2008-09-16 | 2010-03-25 | Playtex Products, Llc. | Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same |
WO2010033832A2 (en) | 2008-09-19 | 2010-03-25 | Evestra, Inc. | Estriol formulations |
EP2174650A1 (en) | 2008-10-08 | 2010-04-14 | Polichem SA | Modified release emulsions for application to skin or vaginal mucosa |
CA2740509A1 (en) | 2008-10-30 | 2010-05-06 | Medlite A/S | Formulation for treatment of vaginal dryness |
WO2010053546A2 (en) | 2008-11-04 | 2010-05-14 | Anchor Therapeutics, Inc. | Crf1 receptor compounds |
US20110294738A1 (en) | 2008-11-04 | 2011-12-01 | Yong Ren | Pthr1 receptor compounds |
WO2010053547A2 (en) | 2008-11-04 | 2010-05-14 | Anchor Therapeutics, Inc. | Cxcr5 receptor compounds |
US20120028888A1 (en) | 2008-11-04 | 2012-02-02 | Jay Janz | Apj receptor compounds |
CN102202678A (zh) | 2008-11-04 | 2011-09-28 | 安科治疗公司 | Cxcr4受体化合物 |
EP2218447B1 (en) | 2008-11-04 | 2017-04-19 | PharmaSol GmbH | Compositions containing lipid micro- or nanoparticles for the enhancement of the dermal action of solid particles |
EP2376071A4 (en) | 2008-11-14 | 2014-04-16 | Univ Ewha Ind Collaboration | METHOD FOR THE PRODUCTION OF MICRO BEADS AND MICRO BEADS MADE THEREFOR |
US8394759B2 (en) | 2008-11-21 | 2013-03-12 | Cymbiotics, Inc. | Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes |
WO2010068500A2 (en) | 2008-11-25 | 2010-06-17 | Evestra, Inc. | PROGESTATIONAL 3-(6,6-ETHYLENE-17b-HYDROXY-3-OXO-17a-PREGNA-4-ENE-17a -YL) PROPIONIC ACID g-LACTONES |
WO2010063080A1 (en) | 2008-12-05 | 2010-06-10 | Commonwealth Scientific And Industrial Research Organisation | Amphiphile prodrugs |
US8664207B2 (en) | 2008-12-06 | 2014-03-04 | Intra-Cellular Therapies, Inc. | Organic compounds |
ES2544976T3 (es) | 2008-12-06 | 2015-09-07 | Intra-Cellular Therapies, Inc. | Compuestos de 4,5,7,8-tetrahidro-2H-imidazo[1,2-a]pirrolo[3,4-e]pirimidina como inhibidores de la PDE1 |
JP5778582B2 (ja) | 2008-12-06 | 2015-09-16 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
AU2009322899A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2010065152A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
GEP20146029B (en) | 2008-12-06 | 2014-02-10 | Intracellular Therapies Inc | Organic compounds |
CN102281870B (zh) | 2008-12-10 | 2015-03-04 | 安徽中人科技有限责任公司 | 新型控释组合物 |
EP2378872A4 (en) | 2008-12-18 | 2012-05-16 | B Eugene Guthery | TREATMENT PLAN FOR ACNE VULGARIS |
EP2384198A4 (en) | 2008-12-30 | 2012-08-08 | Endogenx Inc | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL INJURIES |
EP2381957B1 (en) | 2009-01-13 | 2015-01-07 | Lubris LLC | Therapeutic modulation of vaginal epithelium boundary lubrication |
CN102291992A (zh) | 2009-01-26 | 2011-12-21 | 哈尔·维特 | 同期发情制剂和有效的无cidr方案 |
EP2391358A1 (en) | 2009-01-27 | 2011-12-07 | Wisconsin Alumni Research Foundation | Therapeutic treatment of cancer and dysplasia of the cervix or vagina using estrogen antagonists |
WO2010088409A2 (en) | 2009-01-30 | 2010-08-05 | Emory University | Methods of neuroprotection using neuroprotective steroids and a vitamin d |
WO2010093834A2 (en) | 2009-02-12 | 2010-08-19 | Incube Labs, Llc | Skin penetrating device and method for subcutaneous solid drug delivery |
US8202736B2 (en) | 2009-02-26 | 2012-06-19 | The Governing Council Of The University Of Toronto | Method of hormone extraction using digital microfluidics |
EP2448406B1 (en) | 2009-02-26 | 2016-04-20 | Relmada Therapeutics, Inc. | Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use |
WO2010104937A2 (en) | 2009-03-10 | 2010-09-16 | Northwestern University | Lateral flow strip and uses thereof |
WO2010107922A1 (en) | 2009-03-17 | 2010-09-23 | Duke University | Neuroactive steroid compositions and methods of use for lowering cholesterol |
AU2010224957B2 (en) | 2009-03-17 | 2016-07-21 | Intervet International B.V. | Zoo-technical drug delivery device |
US9005608B2 (en) | 2009-03-24 | 2015-04-14 | Adds Pharmaceuticals Llc | Stabilized solubility-enhanced formulations for oral delivery |
US9198920B2 (en) | 2009-03-27 | 2015-12-01 | Agile Therapeutics, Inc. | Contraceptive transdermal delivery of hormones |
US9011908B2 (en) | 2009-04-06 | 2015-04-21 | Banner Life Sciences Llc | Progesterone solutions for increased bioavailability |
US20120065179A1 (en) | 2009-04-14 | 2012-03-15 | YKI, Ytemiska Institutet AB | Prodrug comprising beta-keto carboxylic acid, beta-keto carboxylic acid salt or beta-keto carboxylic acid ester for drug delivery |
US8694358B2 (en) | 2009-04-14 | 2014-04-08 | Vital Insights Inc. | Systems, methods, and media for survey management |
AU2010237599A1 (en) | 2009-04-14 | 2011-12-08 | Medortus (Uk) Ltd | Gel compositions for administration of pharmaceutically active compounds |
EP2421367A4 (en) | 2009-04-23 | 2012-05-23 | Univ Cincinnati | ALLANTOIN ADMINISTRATION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE AND NEUROLOGICAL TRAUMATISM |
US8344007B2 (en) | 2009-04-23 | 2013-01-01 | The Hong Kong Polytechnic University | Water-soluble polymer-based cantharimides as potentially selective anti-tumor agents |
US20100273730A1 (en) | 2009-04-27 | 2010-10-28 | Innopharmax, Inc. | Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof |
CA2760186C (en) | 2009-04-28 | 2019-10-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
DK3278665T3 (da) | 2009-04-29 | 2020-11-30 | Amarin Pharmaceuticals Ie Ltd | Stabil farmaceutisk sammensætning og fremgangsmåder til anvendelse deraf |
US8568374B2 (en) | 2009-05-04 | 2013-10-29 | Merck Sharp & Dohme B.V. | Intrauterine system |
CN102438452B (zh) | 2009-05-08 | 2015-02-25 | 乔治亚州大学研究基金会 | 包含cdk抑制剂的化合物和组合物以及用于癌症治疗的方法 |
GB0908129D0 (en) * | 2009-05-12 | 2009-06-24 | Innovata Ltd | Composition |
WO2013170052A1 (en) | 2012-05-09 | 2013-11-14 | Sio2 Medical Products, Inc. | Saccharide protective coating for pharmaceutical package |
CA2761538A1 (en) | 2009-05-20 | 2010-12-23 | Lingual Consegna Pty Ltd | Buccal and/or sublingual therapeutic formulation |
US8658628B2 (en) | 2009-06-18 | 2014-02-25 | Karan Y. Baucom | Hormone delivery system and method |
US8815261B2 (en) | 2009-06-19 | 2014-08-26 | Medrx Co., Ltd. | Composition for external application comprising aripiprazole and organic acid as active ingredients |
MY158476A (en) | 2009-06-23 | 2016-10-14 | Bayer Ip Gmbh | Pharmaceutical composition for emergency contraception |
FR2947178B1 (fr) | 2009-06-29 | 2012-07-06 | Effik | Composition pharmaceutique a base de progesterone micronisee et ses utilisations |
CN101940790B (zh) | 2009-07-01 | 2012-07-25 | 润和生物医药科技(汕头)有限公司 | 一种新型促渗剂组合物及其在透皮给药系统中的应用 |
KR101426125B1 (ko) | 2009-07-06 | 2014-08-06 | 에르피오 세러퓨틱스 인코포레이티드 | 암 세포의 전이 예방을 위한 화합물, 조성물 및 방법 |
DE102009034368A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
DE102009034366A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
US8618083B2 (en) | 2009-07-31 | 2013-12-31 | Duquesne University Of The Holy Spirit | Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer |
KR101118587B1 (ko) | 2009-08-17 | 2012-06-12 | 포항공과대학교 산학협력단 | 감응성 고분자 캡슐 및 그 제조방법 |
US8577716B2 (en) | 2009-09-17 | 2013-11-05 | Therapeuticsmd, Inc. | System and method of ongoing evaluation reporting and analysis |
US10029013B2 (en) | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
US8882748B2 (en) | 2009-10-08 | 2014-11-11 | Palo Alto Research Center Incorporated | Transmucosal drug delivery device and method including chemical permeation enhancers |
US20120269721A1 (en) | 2009-10-12 | 2012-10-25 | The Regents Of The University Of California | Targeted nanoclusters and methods of their use |
US20110086825A1 (en) | 2009-10-13 | 2011-04-14 | Chatroux Sylvia S | Therapeutic vaginal emollient |
CA2814237A1 (en) | 2009-10-15 | 2011-04-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Water soluble drug-solubilizer powders and their uses |
BR112012006925A2 (pt) | 2009-10-16 | 2016-06-07 | Hemoteq Ag | uso de uma composição contendo pelo menos um solvente, pelo menos um agente farmacológico e um mediador de transporte ou uma mistura de mediadores de transporte, método para revestir catéteres de balão e catéteres de balão |
JP5871807B2 (ja) | 2009-10-19 | 2016-03-01 | ザ・ポピュレイション・カウンシル,インコーポレイテッド | ネストロン(nestorone(登録商標))を使用する神経保護およびミエリン修復 |
US8637569B2 (en) | 2009-10-22 | 2014-01-28 | Api Genesis, Llc | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds |
US10080760B2 (en) | 2009-10-27 | 2018-09-25 | Besins Healthcare Luxembourg Sarl | Transdermal pharmaceutical compositions comprising active agents |
EP2506867B1 (en) | 2009-12-02 | 2014-10-08 | Cardio3 Biosciences S.A. | Pharmaceutical compositions for the stimulation of stem cells. |
WO2011073995A2 (en) | 2009-12-14 | 2011-06-23 | Lincoln Pharmaceuticals Limited | Liquid vaginal spray of progesterone |
ES2641613T3 (es) | 2009-12-17 | 2017-11-10 | The Population Council, Inc. | Gel transdérmico de Nestorone®/Estradiol |
EP2512516B1 (en) | 2009-12-18 | 2016-02-17 | The Governing Council Of The University Of Toronto | Injectable polymer composition for use as a cell delivery vehicle |
US20110152840A1 (en) | 2009-12-23 | 2011-06-23 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
CN102596186B (zh) | 2009-12-31 | 2017-08-11 | 索尔-格尔科技有限公司 | 芯稳定的微胶囊、它们的制备方法以及它们的用途 |
BRPI1001367A2 (pt) | 2010-01-04 | 2012-07-17 | Theraskin Farmaceutica Ltda | composição para aplicação tópica |
TWI482645B (zh) | 2010-01-07 | 2015-05-01 | Teikoku Seiyaku Kk | 含有待克菲那(diclofenac)羥乙基吡咯啶之外用油性敷貼劑 |
US8709451B2 (en) | 2010-01-20 | 2014-04-29 | University Of Utah Research Foundation | Stable nanoemulsions for ultrasound-mediated drug delivery and imaging |
CA2787002A1 (en) | 2010-01-25 | 2011-07-28 | Concept Medical Research Private Limited | A method and an insertable medical device for delivering one or more pro-healing agents to a target site within a blood vessel post-deployment of a stent |
ES2773079T3 (es) | 2010-02-08 | 2020-07-09 | Shenzhen Evergreen Therapeutics Co Ltd | Métodos para el uso de progestágeno como sensibilizador de glucocorticoides |
EP2533798A2 (en) | 2010-02-09 | 2012-12-19 | Universität Bremen | P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth |
US20130072466A1 (en) | 2010-02-22 | 2013-03-21 | Industry-Academic Cooperation Foundation, Yeungnam University | Composition containing placenta extracts |
WO2011109809A2 (en) | 2010-03-05 | 2011-09-09 | New Agriculture, Inc | A novel composition of matter for delivering lipid-soluble materials, and a method for producing it |
EP2544707B1 (en) | 2010-03-09 | 2018-11-21 | Dignity Health | Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening |
US20130023823A1 (en) | 2010-03-10 | 2013-01-24 | University Of Florida Research Foundation Inc. | Implantable therapeutic device and methods of making |
ES2384060B1 (es) | 2010-03-24 | 2013-09-23 | Lipotec S.A. | Cápsulas de nanopartículas lipídicas. |
US20130245253A1 (en) | 2010-03-26 | 2013-09-19 | Department Of Veterans Affairs | Conjugated Neuroactive Steroid Compositions And Methods Of Use |
WO2011120084A1 (en) | 2010-03-30 | 2011-10-06 | Phosphagenics Limited | Transdermal delivery patch |
DE102010003494A1 (de) | 2010-03-31 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose |
US20110250259A1 (en) | 2010-04-12 | 2011-10-13 | Kevin Buckman | Method of treating and preventing breast diseases and breast cancer with medicated formula |
CA2796268A1 (en) | 2010-04-13 | 2011-10-20 | Johns Hopkins University | Methods for treatment of sleep-related breathing disorders |
JP5820465B2 (ja) | 2010-04-15 | 2015-11-24 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | Hrtのための極低用量固体経口投与形態 |
TW201138782A (en) | 2010-04-26 | 2011-11-16 | Besins Healthcare Lu Sarl | Low-oil pharmaceutical emulsion compositions comprising progestogen |
CN102258455B (zh) | 2010-05-28 | 2014-09-17 | 上海市计划生育科学研究所 | 一种甾体激素类涂膜剂及其制备方法 |
CA2800838C (en) | 2010-05-28 | 2020-03-10 | Nexgen Dermatologics, Inc. | Combination therapy for skin disorders |
WO2011153138A1 (en) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
JP5894148B2 (ja) | 2010-05-31 | 2016-03-23 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
WO2011153136A1 (en) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
BRPI1002601E2 (pt) | 2010-06-01 | 2020-06-30 | Embrapa Pesquisa Agropecuaria | composição nanoestruturada de uso veterinário para administração de fármacos |
JP2012020991A (ja) | 2010-06-16 | 2012-02-02 | Takasago Internatl Corp | 経皮吸収促進剤、及びこれを含有する皮膚外用製剤 |
EP2582355A2 (en) | 2010-06-17 | 2013-04-24 | Momenta Pharmaceuticals, Inc. | Methods and compositions for promoting hair growth |
US9375437B2 (en) | 2010-06-18 | 2016-06-28 | Lipocine Inc. | Progesterone containing oral dosage forms and kits |
US20110312927A1 (en) | 2010-06-18 | 2011-12-22 | Satish Kumar Nachaegari | Progesterone Containing Oral Dosage Forms and Related Methods |
US20110312928A1 (en) * | 2010-06-18 | 2011-12-22 | Lipocine Inc. | Progesterone Containing Oral Dosage Forms and Related Methods |
WO2011162802A1 (en) | 2010-06-21 | 2011-12-29 | Virun, Inc. | Compositions containing non-polar compounds |
EP2399566A1 (en) | 2010-06-28 | 2011-12-28 | Laboratoire HRA Pharma | Once-a-month method of contraception |
US10849857B2 (en) | 2010-07-28 | 2020-12-01 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
KR101209266B1 (ko) | 2010-06-30 | 2012-12-06 | 한국과학기술연구원 | 생분해성 및 온도 감응성 폴리포스파젠계 자성 고분자, 그의 제조 방법 및 용도 |
EP2407157A1 (en) | 2010-07-13 | 2012-01-18 | Koninklijke Philips Electronics N.V. | Lipid bilayer carrier for drugs or imaging agents |
KR20120011344A (ko) | 2010-07-21 | 2012-02-08 | 에스케이케미칼주식회사 | 고분자 미립구의 제조방법 및 그 방법에 의해 제조된 고분자 미립구 |
BRPI1002486B1 (pt) | 2010-07-22 | 2017-07-18 | Evidence Soluções Farmacêuticas Ltda Epp | Stabilized topical composition and process of obtaining composition stable topic |
US20120046264A1 (en) | 2010-08-17 | 2012-02-23 | Biosante Pharmaceuticals, Inc. | Commercial scale production methods for transdermal hormone formulations |
ES2377616B1 (es) | 2010-09-01 | 2013-02-13 | M. Cristina Fernández Rodríguez | Composición estabilizante para formulaciones de aplicación tópica y utilización de la misma. |
US8435972B2 (en) | 2010-09-02 | 2013-05-07 | Emory University | Method for the treatment of central nervous system cancers and compositions related thereto |
BRPI1003661A2 (pt) | 2010-09-15 | 2013-01-08 | Libbs Farmaceutica Ltda | associaÇço farmacÊutica para tratar e/ou prevenir mioma e/ou endometriose, uso de resveratrol e progestogenio, composiÇço farmacÊutica para tratamento e/ou prevenÇço de mioma e/ou endometriose medicamento para tratamento e/ou prevenÇço de mioma e/ou endometrios, kit e mÉtodo para tratamento e/ou prevenÇço de mioma e/ou endometriose |
US20120064135A1 (en) | 2010-09-15 | 2012-03-15 | Norac Pharma | Benzoyl Peroxide Composition, Methods for Making Same, and Pharmaceutical or Cosmetic Formulations Comprising Same, and Uses Thereof |
ES2386177B1 (es) | 2010-09-21 | 2013-09-23 | Lipotec, S.A. | Nanocapsulas conteniendo microemulsiones |
EP2434285A1 (en) | 2010-09-22 | 2012-03-28 | IMBA-Institut für Molekulare Biotechnologie GmbH | Breast cancer diagnostics |
EP2433644A1 (en) | 2010-09-22 | 2012-03-28 | IMBA-Institut für Molekulare Biotechnologie GmbH | Breast cancer therapeutics |
DE102010047714A1 (de) | 2010-10-06 | 2012-04-12 | Justus-Liebig-Universität | Derivate von Steroidbenzylaminen mit antiparasitärer, antibakterieller, antimykotischer und/oder antiviraler Wirkung |
US20120101073A1 (en) | 2010-10-22 | 2012-04-26 | Galleon Pharmaceutical, Inc. | Novel Method For Treating Breathing Disorders or Diseases |
WO2012055814A1 (en) | 2010-10-25 | 2012-05-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compound inducing lbpa accumulation for inhibiting cell-to-cell transmission of hiv |
WO2012055840A1 (en) | 2010-10-28 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders |
WO2012061695A1 (en) | 2010-11-04 | 2012-05-10 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the treatment of traumatic brain injury |
BR112013012156A2 (pt) | 2010-11-17 | 2017-12-05 | Hexal Ag | sistema terapêutico transdérmico e método de produção de um sistema terapêutico transdérmico |
US20120295911A1 (en) | 2010-11-29 | 2012-11-22 | Galleon Pharmaceuticals, Inc. | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases |
EP2645993B1 (en) | 2010-12-03 | 2016-11-02 | Allergan, Inc. | Pharmaceutical cream compositions comprising oxymetazoline |
JP2014500275A (ja) | 2010-12-06 | 2014-01-09 | フォリカ,インコーポレイテッド | 禿頭症を治療するため、および毛髪の成長を促進するための方法 |
KR101424163B1 (ko) | 2010-12-24 | 2014-08-01 | 주식회사 삼양바이오팜 | 수난용성 약물 함유 서방성 마이크로입자 및 그 제조방법 |
DE102011002934A1 (de) | 2011-01-20 | 2012-07-26 | Bayer Schering Pharma Ag | CB2 Agonisten zur Behandlung und Vorbeugung der Endometriose |
EP2667945A1 (en) | 2011-01-24 | 2013-12-04 | Anterios, Inc. | Oil compositions |
KR20140004186A (ko) | 2011-01-24 | 2014-01-10 | 안테리오스, 인코퍼레이티드 | 표면활성제 조성물 |
TW201309670A (zh) | 2011-01-25 | 2013-03-01 | Kissei Pharmaceutical | 吲哚衍生物或其藥理學上容許之鹽 |
EP2669271A4 (en) | 2011-01-25 | 2014-08-13 | Kissei Pharmaceutical | INDOLE DERIVATIVE AND PHARMACEUTICAL ACCEPTABLE SALT THEREOF |
EP2478898B1 (en) | 2011-01-25 | 2016-03-23 | Industrial Cooperation Foundation Chonbuk National University | Method of regulating fertilizing ability using cyclic ADP-ribose and CD38 |
US20140031323A1 (en) | 2011-02-15 | 2014-01-30 | Ramiro M. Perez | Transdermal hormone composition and combined static-cyclic delivery |
WO2012112883A1 (en) | 2011-02-18 | 2012-08-23 | Yale University | The kras-variant and endometriosis |
WO2012116277A1 (en) | 2011-02-25 | 2012-08-30 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
CA2828877A1 (en) | 2011-03-03 | 2012-09-07 | Vanderbilt University | 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mglur5 negative allosteric modulators and methods of making and using the same |
WO2012121874A1 (en) | 2011-03-04 | 2012-09-13 | Wake Forest University Health Sciences | Encapsulated cells for hormone replacement therapy |
WO2012120365A1 (en) | 2011-03-07 | 2012-09-13 | Aurobindo Pharma Limited | Stable pharmaceutical composition comprising ethinyl estradiol |
WO2012127501A2 (en) | 2011-03-11 | 2012-09-27 | Sanzyme Limited | Composition for improving endometrial thickness during ovarian stimulation |
EP2691114A1 (en) | 2011-03-29 | 2014-02-05 | Principium Europe S.r.l. | Delivery of large molecular weight biologically active substances |
WO2012148799A1 (en) | 2011-04-28 | 2012-11-01 | Board Of Regents, The University Of Texas System | Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
AR082266A1 (es) | 2011-05-13 | 2012-11-28 | Univ Nac Del Litoral | Microparticula inyectable de liberacion controlada |
WO2012156820A1 (en) | 2011-05-15 | 2012-11-22 | Trimel Pharmaceuticals Corp. | Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism |
WO2012158483A2 (en) | 2011-05-16 | 2012-11-22 | Avery Dennison Corporation | Adhesive containing microparticles |
KR101481859B1 (ko) | 2011-05-20 | 2015-01-14 | 에스케이케미칼주식회사 | 초기 약물 방출이 감소된 고분자 미립자의 제조방법 및 그 방법에 의해 제조된 고분자 미립자 |
US9084797B2 (en) | 2011-05-23 | 2015-07-21 | Besins Healthcare Luxembourg Sarl | Progesterone treatment for improving sleep quality |
WO2012166909A1 (en) | 2011-06-03 | 2012-12-06 | Galleon Pharmaceuticals, Inc. | Compositions and methods for treating breathing control disorders or diseases |
US9937335B2 (en) | 2011-06-06 | 2018-04-10 | Oak Crest Institute Of Science | Drug delivery device employing wicking release window |
US10561656B2 (en) | 2011-06-10 | 2020-02-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2012171793A1 (en) | 2011-06-13 | 2012-12-20 | Parthenogen Sagl | Selective cns delivery of mifepristone (ru486) to modulate the timing of the spontaneous lh surge during follicular stimulation cycles |
US20130004619A1 (en) | 2011-06-28 | 2013-01-03 | Kemin Industries, Inc. | Method of Forming Encapsulated Compositions with Enhanced Solubility and Stability |
EP2734189B1 (en) | 2011-07-20 | 2018-08-22 | Perrigo Israel Pharmaceuticals Ltd. | Topical oily foam compositions |
US8951996B2 (en) | 2011-07-28 | 2015-02-10 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
CA2844827A1 (en) | 2011-08-16 | 2013-02-21 | Merck Sharp & Dohme Corp. | Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions |
KR101302557B1 (ko) | 2011-08-16 | 2013-09-02 | 충북대학교 산학협력단 | 생리활성물질 함유 미세입자를 포함하는 약물전달계가 고정화된 고분자 생체 재료의 제조방법 |
WO2013028639A1 (en) | 2011-08-19 | 2013-02-28 | The Trustees Of Princeton University | C-halogen bond formation |
WO2013032934A1 (en) | 2011-08-26 | 2013-03-07 | Aegis Therapeutics, Llc | Compositions and methods thereof for oral administration of drugs |
KR101494594B1 (ko) | 2011-08-30 | 2015-02-23 | 주식회사 종근당 | 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
WO2013035101A1 (en) | 2011-09-11 | 2013-03-14 | Minovia Therapeutics Ltd. | Compositions of functional mitochondria and uses thereof |
US20150064155A1 (en) | 2011-09-23 | 2015-03-05 | Trustees Of Tufts College | Methods for treatment of cervical insufficiency |
DE102011083595A1 (de) | 2011-09-28 | 2013-03-28 | Bayer Pharma AG | Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose |
EP2763679A4 (en) | 2011-10-07 | 2016-06-01 | Univ Florida State Res Found | PROPHYLACTIC AND POSTACLE USE OF PROGESTERONE FOR BETTER TREATMENT RESULTS IN BRAIN DISORDER |
US8721331B2 (en) | 2011-10-11 | 2014-05-13 | Puthalath Koroth Raghuprasad | Oral transmucosal drug delivery device |
EP2768666A4 (en) | 2011-10-17 | 2015-07-15 | Univ Temple | BETA-CYCLODEXTRIN-COATED SILICONE ACID PARTICLE FOR THE REMOVAL OF POLLUTION EMITTED FROM WASTEWATER |
US9120766B2 (en) | 2011-10-21 | 2015-09-01 | Amri Ssci, Llc | Methods of making cocrystals |
US20140271884A1 (en) | 2011-10-25 | 2014-09-18 | The Trustees Of Princeton University | High-loading nanoparticle-based formulation for water-insoluble steroids |
US20130116215A1 (en) | 2011-10-28 | 2013-05-09 | Mireia Coma | Combination therapies for treating neurological disorders |
CN103957899A (zh) | 2011-11-04 | 2014-07-30 | 敏捷治疗公司 | 皮肤递送组合物和方法 |
KR20140088197A (ko) | 2011-11-04 | 2014-07-09 | 바이엘 파마 악티엔게젤샤프트 | 18-메틸-6,7-메틸렌-3-옥소-17-프레그느-4-엔-21,17β-카르보락톤, 상기 화합물을 함유하는 약제학적 제제 및 자궁내막증 치료에 있어서 이들의 용도 |
CA2856235A1 (en) | 2011-11-13 | 2013-05-16 | Blanchette Rockefeller Neurosciences Institute | Esters of dcpla for the treatment of neurodegenerative disorders |
US20130122051A1 (en) | 2011-11-15 | 2013-05-16 | Pharmaceutics International, Inc. | Methods of preparing progesterone pharmaceutical compositions |
US20120128683A1 (en) | 2011-11-22 | 2012-05-24 | Shantha Totada R | Autism treatment |
JP6285866B2 (ja) * | 2011-11-23 | 2018-02-28 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然複合ホルモン補充製剤および療法 |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9334538B2 (en) | 2011-12-06 | 2016-05-10 | Annabelle Rodriguez Oquendo | Method for pre-screening and correlation of underlying SCARB1 gene variation to infertility in women and therapeutic use of progestational and other medications in treatment |
WO2013086196A1 (en) | 2011-12-08 | 2013-06-13 | Rigel Pharmaceuticals, Inc. | Topical formulation for administering a compound |
TW201338813A (zh) | 2011-12-12 | 2013-10-01 | Lohmann Therapie Syst Lts | 經皮遞送系統 |
KR101278204B1 (ko) | 2011-12-22 | 2013-06-27 | 경북대학교 산학협력단 | 다중 약물전달계를 갖는 생체의료용 금속합금 재료의 제조방법 |
US9282995B2 (en) | 2011-12-22 | 2016-03-15 | Previvo Genetics, Llc | Recovery and processing of human embryos formed in vivo |
GB201200062D0 (en) | 2012-01-04 | 2012-02-15 | Innotesto Bvba | Estradiol oromucosal liquid compositions |
US20150011466A1 (en) | 2012-01-09 | 2015-01-08 | Anchor Therapeutics, Inc. | APJ Receptor Compounds |
BR112014018439A8 (pt) | 2012-01-26 | 2017-07-11 | Therapeuticsmd Inc | Terapias de reposição de hormônio transdérmica |
HUE035312T2 (en) | 2012-01-31 | 2018-05-02 | Gruenenthal Gmbh | Pharmaceutical patch (1R, 4R) -6'-fluoro-N, N-dimethyl-4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyrano [3,4- b] for transdermal administration of indole] -4-amine |
EP2630952A1 (en) | 2012-02-23 | 2013-08-28 | Novagali Pharma S.A. | Self-preserved oil dispersions comprising boric acid |
WO2013130535A1 (en) | 2012-02-27 | 2013-09-06 | Newgen Biopharma Corporation | Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same |
US20130225412A1 (en) | 2012-02-28 | 2013-08-29 | Soroush Sardari Lodriche | Silicon nanocarrier for delivery of drug, pesticides and herbicides , and for waste water treatment |
JP6169110B2 (ja) | 2012-02-29 | 2017-07-26 | ビー.ブラウン メルズンゲン アーゲーB.Braun Melsungen Ag | ホルモン含有エマルジョン |
WO2013149258A2 (en) | 2012-03-30 | 2013-10-03 | Charles Drew University of Medicine and Science | Compositions and methods for treating or preventing metabolic syndrome disorders |
FR2988609B1 (fr) | 2012-03-30 | 2015-09-04 | Commissariat Energie Atomique | Formulation pour l'hormonotherapie |
FR2988610B1 (fr) | 2012-03-30 | 2014-10-31 | Effik | Progestatif co-micronise avec un polymere portant le groupe pyrrolidone, composition et utilisations |
KR20150009549A (ko) | 2012-04-18 | 2015-01-26 | 지멘스 헬쓰케어 다이아그노스틱스 인크. | 컨주게이트 시약을 제조하기 위한 화합물 및 방법 |
US8716600B2 (en) | 2012-04-18 | 2014-05-06 | Tyco Electronics Corporation | Cable connector systems and methods including same |
US20130301274A1 (en) | 2012-05-09 | 2013-11-14 | Deloren E. Anderson | Led fixture with interchangeable components |
US20130317315A1 (en) | 2012-05-22 | 2013-11-28 | Tony V. Lu | Method of age management |
ITMI20120913A1 (it) | 2012-05-28 | 2013-11-29 | Nicoletta Maxia | Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura |
SG11201407397WA (en) | 2012-05-31 | 2014-12-30 | Repros Therapeutics Inc | Formulations and methods for vaginal delivery of antiprogestins |
US10806740B2 (en) * | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
WO2013192249A1 (en) | 2012-06-18 | 2013-12-27 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US9989539B2 (en) | 2012-06-26 | 2018-06-05 | Temple University—Of the Commonwealth System of Higher Education | Method for detecting injury to the brain |
UA113549C2 (xx) | 2012-06-27 | 2017-02-10 | Біорозкладений засіб доставки лікарських засобів для гідрофобних композицій | |
WO2014009434A1 (en) | 2012-07-11 | 2014-01-16 | Sandoz Ag | Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate |
WO2014012117A1 (en) | 2012-07-13 | 2014-01-16 | South Dakota State University | Compositions and methods for localized drug delivery through mammary papillae |
AR091858A1 (es) | 2012-07-25 | 2015-03-04 | Sova Pharmaceuticals Inc | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) |
WO2014018571A2 (en) | 2012-07-25 | 2014-01-30 | Sova Pharmaceuticals, Inc. | Use of cse inhibitors for the treatment of cutaneous injuries or conditions and sleep-related breathing disorders |
AR091857A1 (es) | 2012-07-25 | 2015-03-04 | Sova Pharmaceuticals Inc | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) |
KR102097663B1 (ko) | 2012-07-27 | 2020-04-06 | 글리아, 엘엘씨 | 눈 질병 및 질환을 위한 조성물 및 치료 |
BR112015001838B1 (pt) | 2012-07-27 | 2022-10-25 | Izumi Technology, Llc | Composição de inibidor de efluxo |
KR101480363B1 (ko) | 2012-07-30 | 2015-01-09 | 한국과학기술연구원 | 분해 속도 조절이 가능한 이온기를 가지는 포스파젠계 고분자, 그의 제조방법 및 그의 용도 |
CN104736176B (zh) | 2012-08-24 | 2017-10-13 | 英特格拉斯疗法有限公司 | 用于增强治疗剂透皮递送的化学组合物和方法 |
EP2708213A1 (en) | 2012-09-13 | 2014-03-19 | PAT&Co bvba | Multipurpose ethylene vinyl acetate fibrous drug delivery systems for long-term implantation or insertion |
WO2014052792A1 (en) | 2012-09-28 | 2014-04-03 | Sio2 Medical Products, Inc. | Halogenated or parylene polymer coating |
DK2716291T3 (da) | 2012-10-08 | 2020-03-02 | Univ Ulm | Kombination af opioider og anticancer-lægemidler til cancerbehandling |
US9381231B2 (en) | 2012-10-09 | 2016-07-05 | University Of Florida Research Foundation, Inc. | Use of relaxin to restore maternal physiology in pregnancies conceived by assisted reproductive technologies |
WO2014066442A2 (en) | 2012-10-24 | 2014-05-01 | Emory University | Methods of managing childhood cerebral injury |
US20140127185A1 (en) | 2012-11-02 | 2014-05-08 | Emory University | Methods and compositions using neuroprotective steroids and thrombolytic agents |
WO2014074846A1 (en) | 2012-11-09 | 2014-05-15 | Celgene Corporation | Methods for the treatment of bone loss |
US20150297733A1 (en) | 2012-11-14 | 2015-10-22 | Trimel Biopharma Srl | Controlled release topical testosterone formulations and methods |
EP2732824A1 (en) | 2012-11-16 | 2014-05-21 | Ceva Sante Animale | Compositions and methods for increasing reproduction performance in non human mammals using alpha-beta-linked follicle stimulating hormone |
US9651561B2 (en) | 2012-11-20 | 2017-05-16 | The Brigham And Womens's Hospital, Inc. | Diagnosis and treatment of endometriosis and related conditions |
US20180221389A1 (en) | 2016-12-05 | 2018-08-09 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
US20160051529A1 (en) | 2012-12-11 | 2016-02-25 | Metabolic Solutions Development Company Llc | Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative and other metabolic diseases |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20190022107A1 (en) | 2017-06-08 | 2019-01-24 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20220047609A1 (en) | 2012-12-21 | 2022-02-17 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20200155465A9 (en) | 2012-12-21 | 2020-05-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9498539B2 (en) | 2012-12-27 | 2016-11-22 | Molly Sandra Shoichet | Affinity-based controlled release system |
KR101586789B1 (ko) | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
US20140186332A1 (en) | 2012-12-28 | 2014-07-03 | NX Pharmagen | Biomarkers of preterm birth |
US8992951B2 (en) | 2013-01-09 | 2015-03-31 | Sapna Life Sciences Corporation | Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma |
US20140370084A1 (en) | 2013-06-18 | 2014-12-18 | Therapeuticsmd, Inc. | Estradiol formulations and therapies |
MX2016005092A (es) | 2013-10-10 | 2016-08-17 | Therapeuticsmd Inc | Composiciones farmaceuticas de estradiol insertadas en la vagina y metodos. |
CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
AU2015296609A1 (en) | 2014-07-29 | 2016-12-22 | Therapeuticsmd, Inc. | Transdermal cream |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US9911629B2 (en) | 2016-02-10 | 2018-03-06 | Taiwan Semiconductor Manufacturing Company, Ltd. | Integrated passive device package and methods of forming same |
JP2019513709A (ja) | 2016-04-01 | 2019-05-30 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | ステロイドホルモン薬学的組成物 |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
MX2018011706A (es) | 2016-04-01 | 2019-06-10 | Therapeuticsmd Inc | Composicion farmaceutica de hormona esteroide. |
US20170281647A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US20180280410A1 (en) | 2017-04-03 | 2018-10-04 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
-
2012
- 2012-11-21 JP JP2014543585A patent/JP6285866B2/ja active Active
- 2012-11-21 CA CA2856520A patent/CA2856520C/en not_active Expired - Fee Related
- 2012-11-21 MX MX2014006256A patent/MX365818B/es active IP Right Grant
- 2012-11-21 LT LTEPPCT/US2012/066406T patent/LT2782584T/lt unknown
- 2012-11-21 HU HUE12850845A patent/HUE055562T2/hu unknown
- 2012-11-21 RS RS20211088A patent/RS62297B1/sr unknown
- 2012-11-21 WO PCT/US2012/066406 patent/WO2013078422A2/en active Application Filing
- 2012-11-21 HR HRP20211377TT patent/HRP20211377T1/hr unknown
- 2012-11-21 EP EP12850845.4A patent/EP2782584B1/en not_active Revoked
- 2012-11-21 PT PT128508454T patent/PT2782584T/pt unknown
- 2012-11-21 US US13/684,002 patent/US8633178B2/en active Active
- 2012-11-21 ES ES12850845T patent/ES2885523T3/es active Active
- 2012-11-21 BR BR112014012444-2A patent/BR112014012444B1/pt active IP Right Grant
- 2012-11-21 EP EP21177701.6A patent/EP3936133A1/en active Pending
- 2012-11-21 PL PL12850845T patent/PL2782584T3/pl unknown
-
2013
- 2013-01-25 US US14/125,554 patent/US9248136B2/en not_active Expired - Fee Related
- 2013-12-06 US US14/099,545 patent/US8846648B2/en active Active
- 2013-12-06 US US14/099,562 patent/US8987237B2/en active Active
- 2013-12-06 US US14/099,571 patent/US8846649B2/en active Active
-
2014
- 2014-09-03 US US14/475,814 patent/US8993548B2/en active Active
- 2014-09-03 US US14/475,864 patent/US8993549B2/en active Active
- 2014-09-03 US US14/476,040 patent/US9114146B2/en active Active
- 2014-09-03 US US14/475,946 patent/US9114145B2/en active Active
-
2015
- 2015-08-19 US US14/830,398 patent/US20150352126A1/en not_active Abandoned
-
2017
- 2017-09-11 JP JP2017173842A patent/JP6656215B2/ja not_active Expired - Fee Related
-
2018
- 2018-08-16 US US16/104,101 patent/US11793819B2/en active Active
-
2020
- 2020-05-27 US US16/885,094 patent/US11103516B2/en active Active
-
2021
- 2021-12-08 FR FR21C1058C patent/FR21C1058I2/fr active Active
-
2023
- 2023-09-15 US US18/468,665 patent/US20240115584A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6285866B2 (ja) | 天然複合ホルモン補充製剤および療法 | |
JP7198177B2 (ja) | 天然の併用ホルモン補充療法剤及び治療 | |
MX2014015900A (es) | Formulaciones de progesterona. | |
AU2012340589B2 (en) | Natural combination hormone replacement formulations and therapies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151104 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160712 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160909 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170111 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170509 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170911 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20171027 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20171026 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180109 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180202 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6285866 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |